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DEUBIQUITINATING ENZYMES PROMOTE CANCER PROGRESSION AND
METASTASIS VIA REGULATING PROTEIN STABILITY

Zhenna Xiao, B.S.
Advisory Professor: Li Ma, Ph.D.

Deubiquitinating enzymes (DUBs, also called deubiquitinases) are
enzymes that remove monoubiquitin or polyubiquitin chains from target
proteins. DUBs have critical roles in cell homeostasis and signal transduction,
as they regulate protein degradation, subcellular localization, and proteinprotein interaction. Deregulation of DUBs contributes substantially to tumor
formation and progression, and therefore targeting DUBs may be a promising
cancer therapy strategy. My dissertation focuses on identifying the DUBs of
EZH2 and SNAI1, two proteins critical for cancer progression and metastasis,
and establishing these DUBs as promising anti-cancer targets.
EZH2, the catalytic component of the PRC2 complex, silences gene
transcription by histone methylation. High levels of EZH2 are a marker of
advanced breast cancer and correlate with poor clinical outcomes in many
cancers. Although EZH2 enzymatic inhibitors have shown antitumor effects in
EZH2-mutated lymphoma and ARID1A-mutated ovarian cancer, many cancers
do not respond, because EZH2 can promote cancer independently of its histone
methyltransferase activity. Here we identified ZRANB1 (also called Trabid) as an
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EZH2 deubiquitinase. ZRANB1 binds, deubiquitinates, and stabilizes EZH2.
Depletion of ZRANB1 in breast cancer cells results in EZH2 destabilization and
growth inhibition. Systemic delivery of ZRANB1 siRNA leads to marked antitumor
and antimetastatic effects in preclinical models of triple-negative breast cancer
(TNBC). A small-molecule inhibitor of ZRANB1 destabilizes EZH2 and inhibits
the viability of TNBC cells. In breast cancer patients, ZRANB1 levels correlate
with EZH2 levels and survival outcomes. These findings suggest the therapeutic
potential for targeting the EZH2 deubiquitinase ZRANB1.
SNAI1 (also known as Snail or SNAIL1), a major transcription factor
inducing

the

epithelial-mesenchymal

transition

(EMT),

promotes

tumor

metastasis and induces resistance to apoptosis and chemotherapy. Here we
identified USP37 as a SNAI1 deubiquitinase. USP37 binds, deubiquitinates, and
stabilizes SNAI1. Overexpression of the wild-type USP37, but not its catalytically
inactive mutant C350S, promotes cancer cell migration. Depletion of USP37
inhibits cancer cell migration, which can be reversed by SNAI1 overexpression.
Taken together, USP37 is a SNAI1 deubiquitinase and a potential therapeutic
target to inhibit tumor metastasis.
In summary, our studies identified the EZH2 deubiquitinase ZRANB1 and
the SNAI1 deubiquitinase USP37 as two promising targets to prevent tumor
progression and metastasis.
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1.1 Protein ubiquitination and degradation
Ubiquitin (Ub) is a highly conserved polypeptide consisting of 76 amino
acids. Protein ubiquitination is a multistep posttranslational modification process
in which a ubiquitin is covalently added to the protein substrate through a
cascade of reactions involving ubiquitin activation by a ubiquitin-activating
enzyme (E1), followed by its transfer to a lysine residue on the substrate, which
is catalyzed by ubiquitin-conjugating enzymes (E2) and ubiquitin ligases (E3)
(Figure 1) (1-3). In addition, another class of polyubiquitin ligases, E4, was
identified as a ubiquitin chain elongation factor family required for polyubiquitin
chain assembly for certain monoubiquitinated proteins (4, 5).
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Figure

1.

Ubiquitin

ligases,

deubiquitinating

enzymes,

and

other

components in the ubiquitination pathway.
Ubiquitin is activated by a ubiquitin-activating enzyme (E1), followed by its
transfer to a lysine residue on the substrate, which is catalyzed by ubiquitinconjugating enzymes (E2) and ubiquitin ligases (E3). Deubiquitinases (DUBs)
reverse this process by removing polyubiquitin chains or monoubiquitin from
target

proteins,

thereby

rescuing

proteins

from

proteasome-dependent

degradation or modulating non-proteasomal processes.

2

Ubiquitin contains seven lysines, which lead to seven kinds of polyubiquitin
chains, linked at K6, K11, K27, K29, K33, K48, and K63. Depending on the
specific lysine residue, protein degradation, localization, activity and lysosomedependent recycling can be regulated (3, 6, 7). Whereas K63-linked
polyubiquitination alters the substrate’s subcellular localization, affects its activity,
and modulates its interaction with other proteins, all other polyubiquitin linkages
have been reported to target proteins for degradation via the proteasome (3, 7).
In addition, the linear ubiquitin chain assembly complex (LUBAC) can assemble
ubiquitin chains through the N-terminal amino group of methionine (Met1) to form
the Met1-linked ubiquitination (also referred to linear ubiquitination), an atypical
nondegradative ubiquitin modification (8). Met1-linked ubiquitination plays an
important role in regulating signaling pathways such as the tumor necrosis factor
(TNF)-signaling

and

NF-κB

signaling

pathways

(8,

9).

Notably,

both

monoubiquitin and polyubiquitin chains have been revealed to regulate protein
endocytosis and nuclear translocation (3).
After E1 activates the ubiquitin in an ATP-dependent manner and E2
conjugates ubiquitin to yield an E2-Ub thioester intermediate, E3, the enzymes
that ligate ubiquitin to protein substrates, impart substrate specificity via bringing
together the right E2-Ub intermediate with the specific target protein (1-3). About
600-1000 E3s have been identified in humans, and are classified into three
families: the really interesting new gene (RING), homology to E6AP C terminus
(HECT), and RING-between-RING (RBR) families (10). The substrate specificity
of E3s may depend on the type of ubiquitin chains and other factors like post-
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translational modifications, such as phosphorylation or hydroxylation, of substrate
proteins (11). The different substrate-binding domains may also determine the
target protein specificity. For example, SKP1-Cullin1-F-box protein (SCF)
complexes, belonging to the RING family of E3 ligases, consist of Rbx1, Cul1,
Skp1 and various F-box proteins. Importantly, the distinct substrate-binding
domains of different F-box proteins in SCF complexes allow the formation of
multiple E3s, each with its own targeting specificity (11, 12).
A better understanding of the function of protein ubiquitination provides
important information for deciphering a broad variety of cellular processes such
as cell cycle, DNA repair and others. Importantly, protein ubiquitination can alter
protein subcellular localization, affect protein activity, and modulate proteinprotein interactions. For example, Yes-associated protein (YAP), the key
downstream effector in Hippo signaling pathway, is subject to non-proteolytic
K63-linked polyubiquitination by SCFSkp2 E3 ligase complex. This non-proteolytic
polyubiquitination of YAP enhances its interaction with the nuclear binding
partner TEAD and therefore promotes the nuclear localization and transcriptional
activity of YAP protein (13). K63-linked polyubiquitination also has a critical role
in regulating dynamic stimulus-dependent protein-protein interactions in the TNFNF-κB signaling

pathway

(14).

Another

important

function

of

protein

ubiquitination is the induction of proteasome-mediated protein degradation.
Although extracellular proteins are mainly degraded within the lysosome, most
intracellular proteins are degraded via the ubiquitin-proteasome pathway (15-17).
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In this pathway, ubiquitination of a protein leads to its recognition by the 26S
proteasome and then its degradation into small peptides by proteolysis (16, 18).
Protein ubiquitination contributes substantially to the regulation of key
cancer-related proteins and pathways. Several E3 ligases have been shown to
act as oncoproteins or tumor suppressors. For example, cancer-predisposing
mutations of BRCA1 inactivate its catalytic activity, suggesting that the tumor
suppressor role of BRCA1 is associated with its E3 ligase function and correlates
with protein ubiquitination (19, 20). Furthermore, the SCFSkp2 E3 ligase complex
targets the CDK inhibitor p27 for ubiquitination and degradation and plays an
important oncogenic role in breast cancer (21-23). Therefore, understanding the
underlying mechanisms of protein ubiquitination should provide critical
information on blocking tumor progression and metastasis.

1.2 Deubiquitinating enzymes
Deubiquitinating

enzymes

(DUBs,

also

called

deubiquitinases),

a

superfamily of cysteine proteases and metalloproteases, are enzymes that
cleave ubiquitin-protein bonds and catalyze the removal of monoubiquitin or
polyubiquitin chains from target proteins (Figure 1) (3, 24). DUBs have critical
roles in cell homeostasis and signal transduction, and deregulation of DUBs
contributes substantially to tumor formation and progression. In many cancer
types, growing numbers of DUBs are found to be aberrantly expressed.
Depending on their substrates, specific DUBs can either promote or suppress
many types of cancer. Deciphering the underlying mechanisms of these DUBs
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may provide critical information on how to block tumor progression and
metastasis.
The human genome encodes approximately 100 DUBs, which can be
classified into six families: ubiquitin-specific proteases (USPs), ubiquitin carboxyterminal hydrolases (UCHs), ovarian-tumor proteases (OTUs), Machado-Joseph
disease protein domain proteases (MJDs), JAMM/MPN domain-associated
metallopeptidases (JAMMs), and the monocyte chemotactic protein-induced
protein (MCPIP) family (3, 25). The USP family is the largest and most diverse
DUB family. Members of this family have a conserved catalytic domain that
consists of three subdomains resembling the thumb, fingers, and palm of the
right hand (26). DUBs in the UCH family, the first structurally characterized DUB
family, have six or seven β-sheets surrounded by eight α-helices, which act as a
gate to preclude large substrates from getting access to the catalytic core located
at the bottom of the DUB (27, 28). Thus, UCH family members can only target
small peptides from the C terminus of ubiquitin. The OTU domain was initially
identified in an ovarian tumor gene, which consists of five β-sheets interspersed
between two helical domains (29, 30). The MJD family has four members,
including the well characterized ATXN3, which is mutated in Machado-Joseph
disease; the other members are ATXN3L, JOSD1, and JOSD2 (31, 32). Unlike
all other DUB families that are cysteine proteases, the JAMM family members
are zinc metalloproteases (33, 34). Recent structural studies revealed that a
JAMM family member, AMSH-LP (associated molecule with SH3 domain-like
protease), specifically cleaves K63-linked polyubiquitin from the substrate and
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regulates vesicle trafficking (35). The MCPIP family has at least seven members,
all of which consist of an N-terminal ubiquitin association domain, a central
CCCH-type zinc-finger domain, and a C-terminal proline-rich domain (36). The
catalytic domains of the six families share no sequence similarity and have
distinct structures.
Notably, DUBs commonly have multiple substrates and need to select their
substrates. Some DUBs have specificity for certain ubiquitin chain linkages. For
example, some members of the OTU and USP families are K48- or K63-linkage
specific (37, 38). The Fingers subdomains of USP7 and USP14 preferentially
restrict access to K48 and K63 (37). CYLD, a USP family member involved in
cylindromatosis disease, has been reported to specifically antagonize K63-linked
and linear polyubiquitin chains (38, 39). OTUB1, an OTU family member, is
known to be K48-linkage specific. Moreover, some DUBs have specificity for
monoubiquitinated

proteins.

These

DUBs

may

recognize

a

specific

monoubiquitinated sequence context in substrate proteins and then hydrolyze the
monoubiquitin (37). Additionally, some DUBs may contain additional protein
interaction domains to facilitate their interaction with specific substrate proteins,
such as the B-box domain in CYLD and the MYND domain in USP19 (39, 40).
DUBs

can

regulate

proteasome-dependent

or

lysosome-dependent

degradation, protein localization, and recycling (Figure 1) depending on the
specific lysine residue through which the ubiquitin chain is linked. Polyubiquitin
chains linked through K48, and likely K6, K11, K27, K29 and K33, mediate
proteasomal degradation (41). By removing these ubiquitin chains from target
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proteins, DUBs stabilize their protein substrates. For example, stabilization of
NF-κB/RelA by USP48 (42), stabilization of MCL1 by USP9X (43), and
stabilization of PTEN by OTUD3 (44) are associated with cleavage of the K48linked polyubiquitin from the substrate. DUBs can also affect protein localization,
which is usually mediated by the cleavage of K63-linked polyubiquitin from the
target protein. For instance, CYLD antagonizes K63-linked ubiquitination of BCL3
and blocks its nuclear localization (45). DUBs can also inhibit lysosomal
degradation of proteins. One study suggested that ubiquitinated EGFR is
internalized into early endosomes, where USP2a catalyzes deubiquitination of
EGFR, which leads to recycling of EGFR back to the plasma membrane (46).
Because DUBs modulate protein stability, signal transduction, and other nonproteasomal functions, they contribute substantially to the regulation of key
cancer proteins and pathways.

1.3 Deubiquitinating enzymes in cancer treatments
FDA approval of the proteasome inhibitor bortezomib for treating multiple
myeloma validated the concept of targeting the proteasome for cancer treatment
(47). However, extended treatment with bortezomib is associated with drug
resistance and toxicity (48). Therapeutic strategies targeting specific DUBs,
instead of the entire ubiquitin-proteasome system, might be better tolerated (49).
Giving the increasing success in tumor suppression after the inhibition of
DUBs, DUB inhibitors should be a promising anticancer strategy. VLX1570, a
competitive inhibitor of proteasomal DUB activity that does not affect non-
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proteasomal DUBs, was reported to selectively target USP14 and UCHL5 and
induce cell apoptosis in multiple myeloma and Waldenstrom macroglobulinemia
(50, 51). VLX1570 was the first DUB inhibitor to enter phase 1/2 clinical trials for
patients with multiple myeloma, but these trials had to be terminated because of
dose-limiting toxicity. Although no other specific DUB inhibitors have yet entered
clinical trials, progress is being made in developing them as therapeutic
strategies. For instance, cyclopentenone prostaglandins, the first DUB active-site
inhibitors, were shown to induce the accumulation of polyubiquitinated proteins
and to cause apoptosis in colon cancer cells (52). WP1130, a partially selective
DUB inhibitor, triggered rapid accumulation of polyubiquitinated proteins in
aggresomes and induced tumor cell apoptosis (53). P5091, an inhibitor of USP7,
induced apoptosis in multiple myeloma cells (54), whereas inhibitors of the
USP1/UAF1 deubiquitinase complex reversed the resistance of non-small cell
lung cancer cells to cisplatin treatment (55). NSC112200, characterized as a
ZRANB1 inhibitor, induced severe TNBC cell death (56, 57). Moreover,
concurrent inhibition of DUBs and autophagy led to synergistic killing of breast
cancer cells, providing a rationale for combining DUB-targeting agents with other
drugs (58). DUB inhibitors with improved efficacy, specificity, and safety may
emerge as new agents for cancer treatment in the near future.
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Chapter 2: Materials and Methods
Copyright Information:
This chapter is based upon previously published work by Zhang P*, Xiao Z*,
Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C,
Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, Lawhon SE, Siverly AN,
Su X, Li J, Xie X, Cheng X, Liu LC, Chang HW, Chiang SF, LopezBerestein G, Sood AK, Chen J, You MJ, Sun SC, Liang H, Huang Y,
Yang X, Sun D, Sun Y, Hung MC, Ma L. ZRANB1 Is an EZH2
Deubiquitinase and a Potential Therapeutic Target in Breast Cancer,
Cell

Reports,

2018,

doi:

10.1016/j.celrep.2018.03.078

(*:

Co-first

authors). Authors retain the rights to include the article in a thesis or
dissertation (provided that this is not to be published commercially)
whether in full or in part, subject to proper acknowledgment.

2.1 Cell lines
The A549, BT549, HEK293T, MCF10A, MDA-MB-231, MDA-MB157, MDA-MB-436, MDA-MB-468, HCC1806, Hs578T, T47D, MCF7,
Mouse Embryonic Fibroblasts (MEF), and HCT116 cell lines were
obtained from the American Type Culture Collection (ATCC) and cultured
under conditions specified by the manufacturer. The HEK293A cell line
was from Dr. Junjie Chen (MD Anderson Cancer Center) and the
luciferase-expressing LM2 cell line was from Dr. Xiang Zhang (Baylor
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College

of

Medicine);

both

were

cultured

in

DMEM

medium

supplemented with 10% fetal bovine serum (FBS). The SUM149,
SUM159, and SUM229 cell lines were from Dr. Stephen P. Ethier
(Medical University of South Carolina) and were cultured in Ham’s F12
medium supplemented with 5% FBS, 5 µg ml -1 insulin and 1 µg ml -1
hydrocortisone. The ZR75-1 cell line was from Dr. Mien-Chie Hung (MD
Anderson Cancer Center) and the SKBR3 cell line was from Dr. Dihua Yu
(MD Anderson Cancer Center); both were cultured in DMEM/F12
supplemented with 10% FBS. The HMLE cell line was from Dr. Robert A.
Weinberg (Whitehead Institute for Biomedical Research) and was
cultured in complete Mammary Epithelial Cell Growth Medium (MEGM
from Lonza). All cell lines were cultured with 1% penicillin and
streptomycin. Short tandem repeat (STR) profiling and mycoplasma tests
were done by ATCC or MD Anderson’s Characterized Cell Line Core
Facility.

2.2 Chemicals
The chemicals used for treating cells are listed in Table 1.
Chemicals

without

analytical

data

from

the

manufacturer

were

authenticated for identity and purity by ultrahigh pressure liquid
chromatography-mass spectrometry (UPLC-MS) and nuclear magnetic
resonance (NMR) analysis at MD Anderson’s Pharmaceutical Chemistry
Facility.
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Table 1. Chemicals used in this study.
Chemicals

Vendor

GSK126

Selleckchem

MG132

NSC60650

Cat#S7061; CAS: 134657457-9

Santa Cruz

Cat#sc-201270; CAS:

Biotechnology

133407-82-6

Cycloheximide Sigma-Aldrich
NSC112200

Catalog #

Sigma-Aldrich

Cat#C7698; CAS: 66-81-9
Cat#S804983; CAS: 2829338-1

Toronto Research

Cat#D436245; CAS: 137-19-

Chemicals
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2.3 Plasmids and siRNA
The human EZH2 open reading frame (ORF) and its deletion
mutants were from Dr. Jae-Il Park (MD Anderson Cancer Center) as
described previously (59). Full-length EZH2 was subcloned into the
pcDNA3.1-MYC and pBabe-SFB (S-protein, FLAG tag, and streptavidinbinding peptide) vectors. EZH2 domain deletion mutants and domainspecific fragments were generated by PCR (primer sequences are listed
in Table 2). pCDH-MYC-EZH2 was from Dr. Mien-Chie Hung as
described previously (60). pCMV-HA-SUZ12 (plasmid number: 24232)
and pCMV-HA-EED (plasmid number: 24231) were from Addgene. pRK5HA-ubiquitin and the lysine-specific mutants (K6, K11, K27, K29, K33,
K48, and K63) were from Addgene (plasmid number: 17608, 22900,
22901, 22902, 22903, 17607, 17605, and 17606). Sixty-eight human
DUB ORFs were obtained from the Dana-Farber/Harvard Cancer Center
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DNA Resource Core or MD Anderson’s Functional Genomics Core and
individually subcloned into the pBabe-SFB vector using the Gateway
system (Invitrogen). pCLXSU (GFP)-HA-ZRANB1 was from Dr. ShaoCong Sun as described previously (61). Full-length human ZRANB1 and
its deletion mutants were subcloned into the pBabe-SFB vector using the
Gateway system (Invitrogen). The pLKO-EZH2 shRNA vector was from
Dr. Mien-Chie Hung as described previously (62); and the sequence was:
5ʹ-CGGAAATCTTAAACCAAGAAT-3ʹ.

Full-length

human

SNAI1

was

subcloned into the pcDNA3.1-MYC vector by PCR. The pGIPZ-USP37
shRNAs #1 (V2LHS_200776) and #7 (V3LHS_317043) were purchased from
MD Anderson’s Functional Genomics Core. The SFB-USP37 C350S mutant
was generated using a QuikChange XL Site-Directed Mutagenesis Kit
(Agilent Technologies). The following ZRANB1 siRNA oligonucleotides
were

purchased

from

Sigma:

ZRANB1

siRNA

#2,

SASI_Hs02

00350242 (5ʹ-GAAUCGUCCUUCUGCCUUUdTdT-3ʹ) and ZRANB1 siRNA
#5, SASI_Hs01 00155781 (5ʹ-GUGAUCAUCCCAGACCUAAdTdT-3ʹ). The
three USP37 siRNAs oligonucleotides were synthesized by Sigma:
USP37

siRNA

#1

(5ʹ-GAUUUGACAGAAUGAGCGAdTdT-3ʹ),

USP37

siRNA #2 (5ʹ-GAAUAAAGUCAGCCUAGUAdTdT-3ʹ), and USP37 siRNA
#3 (5ʹ-CCAAGGAUAUUUCAGCUAAdTdT-3ʹ). Cells were transfected with
100 nM of the indicated oligonucleotide using the Oligofectamine reagent
(Invitrogen). 48 hours after siRNA transfection, cells were used for
functional assays or collected for western blot analysis.
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Table 2. Cloning primers for mutants.
Construct

Sequence (5'-3')

ZRANB1 1-178

GGGGACAAGTTTGTACAAAAAAGCAGGCTCCATGTCAG

F

AACGTGGAATTAAGTGG

ZRANB1 1-178

GGGGACCACTTTGTACAAGAAAGCTGGGTATTATCAATT

R

AGGTCTGGGATGATCAC

ZRANB1 1-340

GGGGACAAGTTTGTACAAAAAAGCAGGCTCCATGTCAG

F

AACGTGGAATTAAGTGG

ZRANB1 1-340

GGGGACCACTTTGTACAAGAAAGCTGGGTATTATCACA

R

TTGCTGGAATACACTTTGC

ZRANB1 245-

GGGGACAAGTTTGTACAAAAAAGCAGGCTCCATGCTTG

708 F

AAGTAGACTTTAAAAAAC

ZRANB1 245-

GGGGACCACTTTGTACAAGAAAGCTGGGTAtcaTTCATC

708 R

TTCATCATCCTCATCTTC

EZH2∆SET F
EZH2∆SET R
EZH2∆CXC F
EZH2∆CXC R
EZH2-EID+D1 F

GGGGACAAGTTTGTACAAAAAAGCAGGCTCCATGGGCC
AGACTGGGAAGAAATCTGAG
GGGGACCACTTTGTACAAGAAAGCTGGGTATCAATGCT
TTTTGGAGCCCCGCTGAATAC
TCCAAGGAAAAAGAAGAGGAAACCTATTGCTGGCACCA
TCTGACGTGG
CCACGTCAGATGGTGCCAGCAATAGGTTTCCTCTTCTTT
TTCCTTGGA
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCATGGGCC
AGACTGGGAAGAAATCTGAG

EZH2-EID+D1

GGGGACCACTTTGTACAAGAAAGCTGGGTATCACCCGT

R

GTACTTTCCCATCATAATTTTTTATTAG

EZH2-D2 F
EZH2-D2 R

GGGGACAAGTTTGTACAAAAAAGCAGGCTCCTTTCCTT
CTGATAAAATTTTTGAAGCC
GGGGACCACTTTGTACAAGAAAGCTGGGTATCACCCTC
CAAATGCTGGTAACACTGTGGTCC
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2.4 Mice
Mice used in our study were supplied by and housed in the
Research Animal Support Facility at MD Anderson Cancer Center. Sixweek-old female NSG mice were used for mammary fat pad injection or
intravenous injection of human breast cancer cells to explore the effect
of ZRANB1 in breast cancer progression and metastasis. Six-week-old
C57BL/6J mice were used for toxicity assessment of ZRANB1 siRNA. All
animal experiments were performed in accordance with a protocol
approved by the Institutional Animal Care and Use Committee of MD
Anderson Cancer Center.

2.5 Human tumor samples
Two breast tumor tissue microarrays, BR487b (48 TNBC cases)
and BR1921 (80 invasive ductal carcinoma cases and 80 invasive lobular
carcinoma cases), were purchased from Biomax to determine the
correlation between ZRANB1 and EZH2 protein levels. For survival
analysis, 138 cases of human tumor tissue specimens were obtained
from patients undergoing surgical resection of breast cancer as primary
treatment at China Medical University Hospital (Taichung, Taiwan)
between 2005 and 2008, under the guidelines approved by the
Institutional Review Board, and written informed consent was obtained
from patients in all cases at the time of enrollment.
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2.6 CRISPR-Cas9-mediated gene editing
ZRANB1-knockout cell lines were generated by the CRISPR-Cas9
genome editing system, using a ZRANB1 gene-specific guide RNA
(gRNA) expression vector (sc-402852) and a homology-directed repair
(HDR) vector (sc-402852-HDR) from Santa Cruz Biotechnology. The
ZRANB1

gRNA

sequences

are:

CTTGGAATTGGCTACACGTT-3ʹ;
CAGCAAGCGTACTTCATCTG-3ʹ;

ZRANB1_gR1,

ZRANB1_gR2,
and

ZRANB1_gR3,

5ʹ5ʹ5ʹ-

ACAGTCGACTGTATGCACTT-3ʹ. Cells were co-transfected with the
gRNA expression vector and the HDR vector containing a puromycin
resistance gene, selected by puromycin, and seeded in 96-well plates for
single colony isolation. The isolated clones were subjected to western
blotting analysis and DNA sequencing for knockout validation.

2.7 Lentiviral transduction
To generate cells stably silencing EZH2 (or USP37) protein
expression, virus-containing supernatant was collected 48 hours and
72 hours after co-transfection of pCMV-VSV-G, pCMV Δ8.2, and the
pLKO-EZH2 shRNA vector (or the pGIPZ-USP37 shRNA vector) into
HEK293T cells, and then added to the target cells. 48 hours later, the
infected cells were selected with 1 µg ml -1 puromycin (Gibco, A1113803).
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2.8 Immunoblotting
Western blotting was performed with precast gradient gels (BioRad) using standard methods. Briefly, cultured cells or mice tissues were
lysed in RIPA buffer (Millipore, 20-188) containing protease inhibitors
(Roche). Proteins were separated by SDS-PAGE and blotted onto a
nitrocellulose membrane (Bio-Rad), followed by incubating with the
specific

primary

antibodies.

antibodies

Protein

bands

and
were

peroxidase-conjugated
visualized

by

secondary

chemiluminescence

(Denville Scientific). The following antibodies were used: antibodies
against EZH2 (1:1,000, Cell Signaling Technology, 5246; or 1:2,000, BD
Biosciences, 612667), SUZ12 (1:1,000, Cell Signaling Technology,
3737), EED (1:1,000, Millipore, 09-774), RBBP4 (1:1,000 4633, Cell
Signaling Technology, 4633), ZRANB1 (1:200, Abcam, ab103417),
H3K27me1 (1:1,000, Active Motif, 61015), H3K27me2 (1,1000, Cell
Signaling

Technology,

9728),

H3K27me3

(1:1,000,

Cell

Signaling

Technology, 9733), H3 (1:1,000, Cell Signaling Technology, 4499),
Vinculin (1:5,000, Sigma, V4505, clone VIN-11-5), Lamin A/C (1:1,000,
Cell

Signaling

Technology,

2032),

β-actin

(1:1,000,

Santa

Cruz

Biotechnology, sc-47778), GAPDH (1:3,000, ThermoFisher Scientific,
MA5-15738), HSP90 (1:2,000, BD Biosciences, 610419), ubiquitin
(1:1,000, Santa Cruz Biotechnology, sc-271289, clone 1213; or 1:000,
Santa Cruz Biotechnology, sc-8017, clone P4D1), FLAG (1:5,000, Sigma,
F3165, clone M2; or 1:2,000, Sigma, F7425), HA (1:2,000, Santa Cruz
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Biotechnology, sc-7392), MYC (1:2,000, Santa Cruz Biotechnology, sc40, clone 9E10), USP37 (1:2000, Abcam, ab190184), SNAI1 (1:700, Cell
Signaling Technology, 3879, clone C15D3) and V5 (1:2000, Sigma,
V8012, clone V5-10). The ImageJ program was used for densitometric
analysis of the western blots, and the quantification results were
normalized to an internal control.

2.9 Purification of SFB-tagged proteins from mammalian cells
HEK293T cells were transfected with SFB-tagged GFP, USP29,
USP37, or USP37 C350S proteins. 48 hours later, cells were collected and
lysed in NETN buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM
EDTA, 0.5% Nonidet P-40) containing protease inhibitors (Roche),
followed by pull down with Streptavidin Sepharose beads (Sigma-Aldrich,
GE17-5113-01) at 4°C for 2 hours. The beads were washed with NETN
buffer for 3 times, 10 minutes for each time. The beads were then
incubate in Biotin (Sigma) solution (1-2mg ml -1 , dissolved in NETN lysis
buffer) at 4°C for 2 hours to elute the SFB-tagged proteins.

2.10 Immunoprecipitation and pulldown assays
Cells were lysed in NETN buffer or CHAPS buffer (25 mM Tris-HCl,
pH 7.5, 120 mM NaCl, 1 mM EDTA, 0.33% CHAPS) containing protease
inhibitors. For immunoprecipitation of endogenous EZH2 protein, cell
extracts (lysed in CHAPS buffer) were pre-cleared with protein-A/G
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beads and IgG, followed by incubation with an EZH2-specific antibody
(BD Biosciences, 612667) or IgG at 4°C for 12 hours and pulldown with
magnetic protein-A/G beads (ThermoFisher, 88803) at room temperature
for 1 hour. The beads were washed with Tris-buffered saline (TBS)
containing 0.05% Tween-20 and CHAPS buffer. The bound proteins were
eluted by incubation with 2× Laemmli buffer at room temperature for 10
minutes with mixing. For immunoprecipitation of tagged proteins, cell
extracts were pre-cleared with protein-A/G beads, followed by incubating
with anti-MYC agarose beads (ThermoFisher Scientific, 20168) or antiHA magnetic beads (ThermoFisher Scientific, 88836) overnight at 4°C.
To pulldown SFB-tagged proteins, cell extracts were incubated with Sprotein beads (Millipore, 69704) at 4°C for 2 hours.

2.11 In vitro binding assay
For the EZH2 in vitro binding assay, purified GST-EZH2 (Abnova,
H00002146-P01)

was

incubated

with

purified

His-ZRANB1

(R&D

Systems, E-560-050), followed by pulldown with nickel magnetic agarose
beads (Sigma, H9914). For the SNAI1 in vitro binding assay, purified
His-SNAI1 (Abcam, ab134870) was incubated with mammalian purified
SFB-DUBs, followed by pulldown with S-protein beads at 4°C for 2
hours. After the pulldown assay, the nickel magnetic agarose beads or
S-protein beads were washed with NETN buffer and the bound proteins
were eluted by boiling in 1× Laemmli buffer.
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2.12 RNA-Seq analysis
RNA was isolated from LM2-scramble siRNA, LM2-ZRANB1 siRNA,
LM2-scramble shRNA, and LM2-EZH2 shRNA cells using the RNeasy
Mini Kit (Qiagen, 74104). The NEBNext® Ultra™ Directional RNA Library
Prep Kit for Illumina® (New England BioLabs, E7420S) was used for
library preparation. Briefly, 2 µg of RNA was purified using the
Poly(A)Purist™ MAG Kit (Invitrogen, AM1922) to enrich polyA+ mRNA
according to the manufacturer’s protocol. Adaptor-ligated products were
purified with Agencourt AMPure XP beads (Beckman Coulter, Inc.,
A63880) and amplified with PCR to generate the cDNA library. Library
quantity was determined by the Qubit dsDNA HighSensitivity Assay Kit
(Invitrogen, Q32854), and the length distribution of the library was
monitored using the Agilent 2100 bioanalyzer with DNA 1000 Kit (Agilent,
5067-1504).

Normalized libraries were subjected to an Illumina

NextSeq™500 using the NextSeq 500/550 Mid Output v2 Kit (150 cycles)
(Illumina, FC-404-2001). The quality of fastq files was determined by
Fastqc

(V0.11.5,

https://www.bioinformatics.babraham.ac.uk/projects/fastqc/).

The

pair-

ended reads were mapped to human hg19 (Feb 2009, UCSC) genome
using Tophat (V2.1.1, https://github.com/infphilo/tophat); only uniquely
mapped

reads

were

extracted

http://samtools.sourceforge.net/)
expression

analysis.

The

as

Pearson

using
inputs

SAMtools
for

correlation

differential
coefficient

(V1.5,
gene
among
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biological replicates was 0.94-0.99, indicating high reproducibility. The
results from RSeQC (V2.6.4, http://rseqc.sourceforge.net/) also indicated
high

data

quality.

Cufflinks

(V2.2.1,

http://cole-trapnell-

lab.github.io/cufflinks) was used to assemble the transcriptome using
RefSeq (Sep 7, 2015) annotation file and quantitate the gene expression
level with fragments per kb of transcript per million mapped reads
(FPKM). Differentially expressed genes (DEGs) were identified using
Cuffdiff

(V2.2.1,

http://cole-trapnell-lab.github.io/cufflinks)

with

the

corrected P value < 0.05 and absolute log2 fold change > 0.7. Principle
Component Analysis (PCA) of all DEGs’ expression among all 12
samples

was

performed

using

Bioconductor

package

DESeq2

(http://bioconductor.org/packages/release/bioc/html/DESeq2.html).

The

heatmap was generated by using R (V3.2.2, “Fire Safety”, https://www.rproject.org/) gplot module.

2.13 Fractionation assay
HEK293T cells were transfected with SFB-tagged ZRANB1 and its
truncation mutants, and fractionation of nuclear and cytoplasmic proteins
was separated by the NE-PER Nuclear and Cytoplasmic Extraction Kit
(ThermoFisher

Scientific,

78833)

according

to

the

manufacturer’s

protocol. After fractionation, Western blot analysis was performed to
analyze full-length ZRANB1 and its truncation mutants in the cytoplasm
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and the nucleus. Vinculin and Lamin A/C were used as markers of the
cytoplasm and nucleus, respectively.

2.14 Immunofluorescence
HEK293T cells co-transfected with SFB-ZRANB1 and MYC-EZH2
were cultured in chamber slides (ThermoFisher Scientific, 154917)
overnight, fixed with formaldehyde at room temperature for 10 minutes,
and then permeabilized with 0.5% Triton X-100 in PBS for 10 minutes.
Cells were then blocked for non-specific binding with 10% goat serum in
PBS at room temperature for 1 hour, and incubated with the antibodies
against FLAG (1:1,000, Sigma, F7425) and MYC (1:800, Santa Cruz
Biotechnology, sc-40, clone 9E10) at 4°C overnight, followed by
incubation with Alexa Fluor 488 goat anti-rabbit IgG (1:600, Invitrogen,
A11008) and Alexa Fluor 549 goat anti-mouse IgG (1:600, Invitrogen,
A11005) at room temperature for 1 hour. Cover slips were mounted on
slides using antifade mounting medium with DAPI (Vector Laboratories,
H-1200). Immunofluorescence images were acquired on a Zeiss LSM880
confocal microscope.

2.15 In vitro DUB activity assay
0.05 µg µL -1 of purified His-ZRANB1 (R&D Systems, E-560-050) or
A20 (Sigma, SRP0444-50UG) was pretreated with 30 µM NSC112200 or
NSC60650 for 10 minutes, and was then incubated with 0.1 µg µL -1 of
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K33-linked di-ubiquitin (R&D systems, UC-101B-025) or K63-linked tetraubiquitin (R&D systems, UCB-310-025) in the presence of the compound
at 37ºC for 1.5 hours in a DUB reaction buffer (50 mM HEPES, pH 7.5,
100 mM NaCl, 2 mM TCEP). Reactions were quenched with 2× Tricine
sample buffer (Bio-Rad, 1610739) at 40°C for 20 minutes. Samples were
then loaded onto a Tris-Tricine gel (Bio-Rad, 4563064) for western
blotting analysis using a ubiquitin-specific antibody (Upstate, 07-375).

2.16 Deubiquitination of EZH2 and SNAI1 in vivo and in vitro
For the in vivo deubiquitination assay, HEK293T or ZRANB1knockout HEK293A cells were transfected as indicated and then treated
with a proteasome inhibitor MG132 (10 µM) for 6 hours. For denaturing,
lysates with 1% SDS were heated at 95°C for 5 minutes, followed by 10fold dilution with lysis buffer (to 0.1% SDS) and sonication, as described
previously (63). The cell extracts were subjected to immunoprecipitation
and western blot analysis with the indicated antibodies. To prepare
ubiquitinated EZH2 as the substrate for the in vitro deubiquitination
assay of EZH2, ZRANB1-knockout HEK293A cells were co-transfected
with HA-ubiquitin (wild-type or the K33-specific mutant) and MYC-EZH2
and then treated with MG132 for 6 hours. Ubiquitinated EZH2 was
purified from the cell extracts with anti-MYC beads. After extensive wash
with NETN buffer, the bound proteins were incubated with purified HisZRANB1 protein (R&D Systems, E-560-050). The in vitro deubiquitination
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reaction

was

performed

as

described

previously

(64).

Briefly,

ubiquitinated EZH2 protein was incubated with purified ZRANB1 in
deubiquitination buffer (50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1 mM
EDTA, 10 mM dithiothreitol, 5% glycerol) at 37°C for 2 hours. After the
reaction, the beads were washed with deubiquitination buffer, and the
bound proteins were eluted by boiling in 1× Laemmli buffer and
subjected to immunoblotting analysis with the indicated antibodies.
Similarly, for preparation of ubiquitinated SNAI1 as the substrate for the
in vitro deubiquitination assay of SNAI1, HEK293T cells were cotransfected with HA-ubiquitin and MYC-SNAI1 and then treated with
MG132 for 6 hours. Ubiquitinated SNAI1 was purified from the cell
extracts with anti-MYC beads. After extensive wash with NETN buffer,
the bound proteins were incubated with purified SFB-tagged GFP,
USP37 or USP37 C350S proteins in deubiquitination buffer at 37°C for 2
hours. The beads were then washed 3 times with deubiquitination buffer,
and the bound proteins were eluted by boiling in 1× Laemmli buffer and
subjected to immunoblotting analysis against the indicated antibodies.

2.17 RNA isolation and quantitative PCR
Total RNA was isolated using the TRIzol reagent (ThermoFisher
Scientific). Reverse transcription was performed with an iScript cDNA
Synthesis Kit (Bio-Rad). The resulting cDNA was used for quantitative
PCR using the TaqMan Gene Expression Assays (Applied Biosystems)
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or SYBR Green reagent (Bio-Rad), and data were normalized to an
endogenous control (GAPDH, β-actin or HSP90). Real-time PCR and
data collection were performed on a CFX96 instrument (Bio-Rad). qPCR
primers and TaqMan probes are listed in Table 3.

2.18 Cell proliferation assay
To measure cell proliferation rates, we plated equal numbers of cells in 24well or 6-well plates. Cells were trypsinized and counted on the indicated days.
Cell counts were obtained from a TC10 Automated Cell Counter (Bio-Rad).

2.19 Migration assay
To measure cell motility, we plated the indicated cells in the top
chamber with the non-coated membrane (24-well insert; pore size, 8 µm;
BD Biosciences) in serum-free medium, and medium supplemented with
serum was used as a chemoattractant in the lower chamber. After
incubating for 18 hours, cells that did not migrate through the pores were
removed with a cotton swab. Then cells on the lower surface of the
membrane were fixed with 10% formalin, stained with 0.2% crystal violet
at room temperature for 45 minutes and then counted.
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Table 3. qPCR primers and Taqman probes.
Gene

Source

Identifier or sequence (5'-3')

ZRANB1 #1

TaqMan (Applied Biosystems)

Hs01008891_g1

ZRANB1 #2

TaqMan (Applied Biosystems)

Hs00406150_m1

ZRANB1 #4

TaqMan (Applied Biosystems)

Hs01008890_g1

ZRANB1 #6

TaqMan (Applied Biosystems)

Mm01165048_m1

ZRANB1 #7

TaqMan (Applied Biosystems)

Mm01138327_m1

EZH2

TaqMan (Applied Biosystems)

Hs01016788_m1

ADRB2

TaqMan (Applied Biosystems)

Hs00240532_s1

DAB2IP

TaqMan (Applied Biosystems)

Hs00368995_m1

ACTIN

TaqMan (Applied Biosystems)

Hs01060665_g1

GAPDH

TaqMan (Applied Biosystems)

Hs02758991_g1

HSP90

TaqMan (Applied Biosystems)

Sp03776498_s1

EED-F

Sigma-Aldrich

ACAGGCCATTTATTTCTCAG

EED-R

Sigma-Aldrich

GTATCAAATCGCCTAACCATC

RBBP4-F

Sigma-Aldrich

GAAATATTCCAGGTTCAGTGG

RBBP4-R

Sigma-Aldrich

AGATATCTTGGCAGTATGACC

SUZ12-F

Sigma-Aldrich

GGATGTAAGTTGTCCAATAAG
G
SUZ12-R

Sigma-Aldrich

GTTTGATTGAGGTCAGGATTC
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2.20 MTT assay
Cells were plated in 96-well plates and treated with the compound
(GSK126, NSC112200, or NSC60650) at indicated concentrations for
indicated times. MTT reagent (ThermoFisher Scientific, V13154) was
added and the cells were incubated at 37°C for 4 hours, and then DMSO
was added and the cells were incubated at 37°C for an additional 10
minutes. Absorbance was measured in a microplate reader at 540 nm.

2.21 Synthesis of modified siRNA oligonucleotides for in vivo
delivery
siRNAs were synthesized at AM Biotechnologies. The sequences
and

chemical

modifications

are:

ZRANB1

siRNA

#2,

5ʹ-

GAAUCGUCCUUCUGCCUUMS2UMS2dTdT-3ʹ; ZRANB1 siRNA #5, 5ʹGUGAUCAUCCCAGACCUAMS2AMS2dTdT-3ʹ (MS2: 2'-O-methyl and
phosphorodithioate). The 21-nt RNAs (sense and antisense strands)
were synthesized on the 1 µmole scale on an Expedite 8909 DNA/RNA
Synthesizer using commercially available 5ʹ-O-dimethoxytrityl-2ʹ-O-tertbutyldimethylsilyl nucleoside (5ʹ-DMT-2ʹ-O-TBDMS nucleoside: ABz,
CAc, GAc, and U) phosphoramidite monomers and in-house produced 5ʹDMT-2ʹ-O-methyl
thiophosphoramidite

nucleoside
monomers

(ABz,
(65-67).

CAc,
All

GAc,

and

oligonucleotides

U)
were

synthesized in DMT-off mode. After synthesis was completed, the solid
support was suspended in ammonium hydroxide-methylamine solution
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(prepared by mixing 1 volume of ammonium hydroxide (28%) with 1
volume of 40% aqueous methylamine) and heated at 65°C for 15 minutes
to release the product from the support and to remove all protecting
groups except the TBDMS group at the 2ʹ-position. The solid support
was filtered and the filtrate was concentrated until dry. The obtained
residue was resuspended in 115 µl of anhydrous DMF and then heated
at 65°C for 5 minutes to dissolve the crude product. Triethylamine (TEA,
60 µl) was added to each solution, and the solutions were mixed gently.
TEA·3HF (75 µl) was added to each solution, and the tubes were then
sealed tightly and incubated at 65°C for 2.5 hours. The reaction was
quenched

with

1.75

ml

of

diethylpyrocarbonate-treated

water.

Purification was performed on an Amersham Biosciences P920 FPLC
instrument fitted with a Mono Q 10/100 GL column (68). The structures
of the modified RNAs were confirmed by ESI-MS and 31P-NMR. The
assembly of the resulting duplexes was confirmed by 4% agarose gel
electrophoresis. For in vivo experiments, ammonium counter cation was
replaced by sodium cation.

2.22 Liposomal nanoparticle preparation
siRNAs for in vivo delivery were incorporated into DOPC liposomes
as previously described (65). In brief, chemically modified siRNA
oligonucleotides and DOPC were mixed in the presence of excess
tertiary butanol at a ratio of 1:10 (siRNA:DOPC). Tween 20 was added to
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the mixture at a ratio of 1:19 (Tween 20:siRNA-DOPC). The mixture was
vortexed, frozen in an acetone-dry ice bath, and lyophilized. Before in
vivo administration, the preparation was hydrated with PBS.

2.23 Animal study
For mammary fat pad injection, NSG mice were anesthetized, and 5
× 104 LM2 cells in growth medium (mixed with Matrigel at a 1:1 ratio)
were injected into the inguinal mammary fat pad. For intravenous
injection, mice were placed in a restrainer, and 2 × 105 LM2 cells in 100
µL PBS were injected through the tail vein. Three days after tumor cell
implantation, we confirmed tumor cell engraftment by bioluminescent
imaging, excluded the outliers, and randomly divided the mice into four
treatment groups: (1) vehicle (PBS); (2) scramble-DOPC; (3) siZRANB1#2-DOPC; and (4) si-ZRANB1#5-DOPC. The treatment was
administered through the tail vein twice weekly at a dose of 250 µg kg-1
body weight till the end point. Tumor size was measured using a caliper,
and tumor volume was calculated using the standard formula 0.5 × L
× W2 (L: the longest diameter, W: the shortest diameter). Metastasis was
quantitated by luciferase imaging of live animals using a Xenogen
IVIS 200 bioluminescence imaging system. Mice were euthanized when
they met the institutional euthanasia criteria for tumor size or overall
health condition. The tumors were removed and weighed. RNA and
protein were extracted from tumor and lung issues for qPCR and

29

Western blot analysis, respectively. The remaining tissues were fixed in
10% buffered formalin overnight, washed with PBS, transferred to 70%
ethanol, embedded in paraffin, sectioned, and stained with hematoxylin
and eosin (H&E). Stained sections were photographed using a Zeiss
Axio Observer Z1 microscope. For toxicity assessment of siRNA, normal
C57BL/6 mice received twice weekly intravenous injection of the vehicle,
DOPC-encapsulated ZRANB1 siRNA (#5), or scramble oligonucleotides
at a dose of 250 µg kg-1 body weight for two weeks. Total body weight
was measured twice a week and liver weight was measured postmortem. Liver sections were examined by a pathologist (M.J.Y) for all
possible pathological conditions.

2.24 Patient study
Two breast tumor tissue microarrays, BR487b (48 TNBC cases)
and BR1921 (80 invasive ductal carcinoma cases and 80 invasive lobular
carcinoma cases), were purchased from Biomax to determine the
correlation between ZRANB1 and EZH2 protein levels. For survival
analysis, 138 cases of human tumor tissue specimens were obtained
from patients undergoing surgical resection of breast cancer as primary
treatment at China Medical University Hospital (Taichung, Taiwan)
between 2005 and 2008, under the guidelines approved by the
Institutional Review Board, and written informed consent was obtained
from patients in all cases at the time of enrollment. Samples were
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deparaffinized and rehydrated. 0.01 M sodium citrate buffer (pH 6.0) was
used to perform antigen retrieval in a microwave oven. To block
endogenous peroxidase activity, the sections were treated with 1%
hydrogen peroxide in methanol for 30 minutes. After 1 hour preincubation in 10% normal serum to prevent non-specific staining, the
samples were incubated with the antibody against ZRANB1 (1:200,
Abcam, ab103417) or EZH2 (1:100, Life Technologies, 366300) at 4 °C
overnight.

The

sections

were

then

incubated

with

a

biotinylated

secondary antibody, followed by incubation with avidin-biotin peroxidase
complex solution (1:100) at room temperature for 1 hour. Color was
developed

with

the

3-amino-9-ethylcarbazole

(AEC)

solution.

Counterstaining was carried out using Mayer’s hematoxylin. A total score
of protein expression was calculated from both the percentage of
immunopositive cells and immunostaining intensity. The chi-square test
and linear regression analysis were used for statistical analysis of the
correlation between ZRANB1 and EZH2. The log-rank test was used to
compare Kaplan-Meier survival curves.

2.25 TCGA data analysis
TCGA

data

were

first

analyzed

using

cBioPortal

(http://www.cbioportal.org/). From TCGA data (including TCGA, TCGA
2015, and TCGA pub), 13 breast cancer samples and 9 ovarian cancer
samples with ZRANB1 gene amplification were used for further analysis
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of the amplicon. The segmented data for all 22 samples were
downloaded from the TCGA Firehose (http://firebrowse.org, version:
20160128), followed by standard GISTIC2 (Genomic Identification of
Significant Targets in Cancer, version 2) analysis using Firehosesuggested parameters.

2.26 Quantification and statistical analysis
Unless otherwise noted, data are presented as mean ± s.e.m., and
Student’s t-test (unpaired, two-tailed) was used to compare two groups
of independent samples. The chi-square test and linear regression
analysis were used for statistical analysis of the correlation between
ZRANB1 and EZH2. The log-rank test was used to compare KaplanMeier survival curves. Methods used for RNA-Seq analysis and TCGA
data

analysis

were

described

above.

P

<

0.05

was

considered

statistically significant.

2.27 Data availability
The RNA-Seq data have been deposited at the Gene Expression
Omnibus (GEO: https://www.ncbi.nlm.nih.gov/geo/) under the accession
number GSE104910.
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Chapter 3: ZRANB1 Stabilizes EZH2 via Deubiquitination and Promotes
Breast Cancer Progression

This chapter is based upon previously published work by Zhang P*, Xiao Z*,
Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C,
Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, Lawhon SE, Siverly AN,
Su X, Li J, Xie X, Cheng X, Liu LC, Chang HW, Chiang SF, LopezBerestein G, Sood AK, Chen J, You MJ, Sun SC, Liang H, Huang Y,
Yang X, Sun D, Sun Y, Hung MC, Ma L. ZRANB1 Is an EZH2
Deubiquitinase and a Potential Therapeutic Target in Breast Cancer,
Cell

Reports,

2018,

doi:

10.1016/j.celrep.2018.03.078

(*:

Co-first

authors). Authors retain the rights to include the article in a thesis or
dissertation (provided that this is not to be published commercially)
whether in full or in part, subject to proper acknowledgment.
3.1 Introduction
Breast cancer is the most common cancer type in women, which
can be divided into five main intrinsic subtypes: luminal A (hormonereceptor positive, HER2 negative, low Ki67 level), luminal B (hormonereceptor positive, HER2 positive or negative, high Ki67 level), basal-like
(estrogen receptor negative, HER2 negative, basal markers positive),
HER2-enriched

(hormone-receptor

negative,

HER2

positive),

and

normal-like breast cancer (hormone-receptor positive, HER2 negative,
low Ki67 level, worse prognosis than luminal A breast cancer) (69).
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Although survival rates for patients with breast cancer have significantly
increased during the past several years owing to the improved screening and
treatment strategies, breast cancer is still the most common invasive cancer and
second main cause of cancer death in women. The majority but not all basal-like
breast cancers are triple-negative breast cancer (TNBC). Although TNBC
constitutes only about 20% of breast cancers, it is considered the most
aggressive

subtype

and

correlates

with

the

worst

clinical

outcomes

(70). Because TNBC lacks expression of estrogen receptor (ER), progesterone
receptor (PR), and HER2, it does not respond to hormone or anti-HER2 therapy.
Neoadjuvant

chemotherapy

(NAC)

with

anthracyclines,

taxanes,

and

cyclophosphamide is the standard of care for TNBC (71). Unfortunately, a large
portion of TNBC patients evolved resistance to NAC, resulting in poor survival
(72). The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib kills metastatic
breast cancers with BRCA1 or BRCA2 mutations. Olaparib is now in phase IIIb
clinical trials for patients with metastatic breast cancer. However, BRCAproficient TNBC is resistant to PARP inhibition and combinations of PARP
inhibitors with other drugs are being sought (73, 74). Several drugs for TNBC are
currently being tested, and other therapeutic strategies warrant further
investigation as well.
EZH2, the catalytic component of the polycomb repressive complex 2
(PRC2), silences gene transcription by methylating histone H3 at lysine 27 (75,
76). EZH2 is mutated or highly expressed in many types of cancer, including
lymphoma (77), melanoma (78), prostate cancer (79), and ovarian cancer (80).
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Importantly, overexpression of EZH2 is a marker of aggressive breast cancer
(81). Experimentally, overexpression of EZH2 has been shown to promote cell
proliferation, tumorigenesis, and metastasis (81-84). Conversely, depletion of
EZH2 leads to growth inhibition. For example, knockdown of EZH2 in a TNBC
cell line, MDA-MB-231, suppressed tumor growth and metastasis in xenograft
models (85, 86). The cancer-promoting function of EZH2 is also supported by
findings from genetically engineered mouse models. For instance, transgenic
overexpression of EZH2 or its gain-of-function mutant in mice led to hyperplasia
and accelerated Myc- or Bcl2-induced lymphomagenesis (87, 88) and Erbb2induced mammary tumorigenesis (89, 90). Moreover, expression of a lymphomaderived hyperactivating mutant of EZH2 from the endogenous locus in mouse B
cells or melanocytes caused high-penetrance lymphoma or melanoma,
respectively (91). These findings have prompted intensive efforts to develop
EZH2 inhibitors.
Two highly specific EZH2 enzymatic inhibitors, GSK126 and EPZ-6438, are
currently in clinical trials for patients with lymphomas (92). Although these EZH2
inhibitors have shown antitumor effects in lymphoma cells with enzyme-activating
mutations of EZH2 (93-95) and in ovarian cancer cells with inactivating mutations
of ARID1A (96), certain cancer cells are resistant to enzymatic inhibition of EZH2
but sensitive to genetic depletion of EZH2, suggesting that the tumor-promoting
function of EZH2 depends on both its catalytic and non-catalytic activity. Indeed,
independently of its PRC2 methyltransferase activity, EZH2 can promote cancer
by stabilizing the PRC2 complex (97), or by acting as a transcriptional coactivator
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of the androgen receptor (98, 99), estrogen receptor (100), β-catenin (100), and
NF-κB (101). Consequently, destroying the EZH2 protein should be more
effective than EZH2 inhibitors in targeting cancers that are dependent on EZH2’s
non-catalytic activity.

3.2 Results
3.2.1 ZRANB1 regulates EZH2 protein level
To evaluate the effect of GSK126 on breast cancer cell proliferation, we
treated two TNBC cell lines, BT549 and a lung-metastatic subline (LM2) of MDAMB-231 cells (102), with this compound. A previously reported GSK126-sensitive
human lung cancer cell line (97), A549, was used as a positive control. In the
presence of 8 µM GSK126, A549 cells showed an approximately 80% reduction
in the number of viable cells in an MTT assay (Figure 2A), whereas BT549 and
LM2 cells showed a modest reduction and no reduction, respectively (Figures
2B and 2C). In all three cell lines, 2 µM GSK126 treatment completely abrogated
histone H3 lysine 27 (H3K27) trimethylation (H3K27me3), the marker of EZH2
activity (Figures 2A-2C), despite no anti-proliferative effect on LM2 cells. On the
other hand, shRNA-mediated silencing of EZH2 expression inhibited the
proliferation of LM2 cells (Figure 2D), suggesting that LM2 cells are responsive
to knockdown of EZH2 but refractory to enzymatic inhibition of EZH2.
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Figure 2. TNBC cells are resistant to enzymatic inhibition of EZH2 but
sensitive to knockdown of EZH2.
(A-C) A549 (A), BT549 (B), and LM2 (C) cells were treated with GSK126 at the
indicated concentrations. 6 days after treatment, viable cells were quantitated by
an MTT assay. Inset: immunoblotting of H3K27me3 and H3. n = 5 biological
replicates. Error bars are s.e.m. This experiment was done by Dr. Peijing Zhang.
(D) 2 × 104 LM2 cells transduced with EZH2 shRNA or a scramble control were
seeded in 24-well plates. Cell numbers were counted at day 2 and day 4. Inset:
immunoblotting of EZH2 and β-actin. n = 3 biological replicates. Error bars are
s.e.m. The P value was calculated from a two-tailed t-test.
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Our hypothesis is that targeting the EZH2 DUB could lead to the
destabilization of EZH2 and inhibit both catalytic and non-catalytic function of
EZH2. To identify the EZH2 DUB, we first screened for EZH2-interacting DUBs
using a panel of 46 DUBs fused to a triple-epitope tag, SFB (S-protein, FLAG
tag, and streptavidin-binding peptide) (103). We co-transfected each SFB-tagged
DUB with MYC-tagged EZH2 into HEK293T cells, pulled down the DUBs with Sprotein beads, and detected physical association of EZH2 with six DUBs: USP22,
USP39, USP44, USP49, USP53, and ZRANB1 (Figure 3A). Reciprocally, each
of these six SFB-tagged DUBs could be pulled down by MYC-EZH2, but not by
MYC-GFP (Figure 3B). To determine whether the six EZH2-interacting DUBs
affect EZH2 protein levels, we transfected them individually into HEK293T cells
and found that only ZRANB1 increased endogeneous EZH2 protein levels
(Figure 3C).
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Figure 3. ZRANB1 interacts with EZH2 and increases EZH2 protein levels.
(A) Six of 46 DUBs physically associated with EZH2. Each SFB-tagged DUB was
co-transfected with MYC-tagged EZH2 into HEK293T cells, followed by pulldown
with S-protein beads and immunoblotting with antibodies against FLAG and
MYC. (B) HEK293T cells were co-transfected with SFB-tagged DUBs and MYCEZH2 or MYC-GFP, followed by immunoprecipitation with anti-MYC beads and
immunoblotting with antibodies against FLAG and MYC. (C) HEK293T cells were
transfected with SFB-tagged DUBs and immunoblotted with antibodies against
EZH2 and β-actin. These experiments were done by Drs. Peijing Zhang and
Shouyu Wang.
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MDA-MB-231 cells were transfected with five ZRANB1 siRNAs individually
and we found that silencing ZRANB1 expression in MDA-MB-231 cells by two
independent siRNAs (#2 and #5) reduced endogenous EZH2 protein levels by
70% and 60%, respectively (Figure 4A). Moreover, overexpression of ZRANB1
in HEK293T cells increased endogenous EZH2 and H3K27 trimethylation levels,
which could be reversed by co-expression of ZRANB1 siRNA (Figure 4B). It
should be noted that knockdown of ZRANB1 did not change mRNA levels of
EZH2 (Figure 4C) or other PRC2 components, EED, RBBP4, and SUZ12
(Figure 4D). We conclude from these findings that ZRANB1 is a positive
regulator of EZH2 protein but not EZH2 mRNA.
To corroborate the siRNA results, we used a CRISPR-Cas9 approach to
knock out ZRANB1 in HEK293A cells that express abundant endogenous
ZRANB1 protein (Figure 4E). Compared with cells transfected with a control
guide RNA (gRNA), two independent clones derived from transfection with the
ZRANB1 gRNA both showed depletion of ZRANB1 (gene editing in the targeted
region was confirmed by sequencing the clones) and downregulation of EZH2
(Figure 4E). Consistent with a reported role of EZH2 in stabilizing the PRC2
complex (97), protein levels of other PRC2 components, SUZ12 and EED, were
decreased in ZRANB1-knockout cells (Figure 4E). Moreover, ablation of
ZRANB1 abrogated H3K27me3, but not H3K27me1 or H3K27me2 (Figure 4E).
Similarly, GSK126 treatment has been shown to diminish H3K27me3 without
affecting H3K27me1 or H3K27me2 at 25-500 nM (93).
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Figure 4. ZRANB1 is a positive regulator of EZH2 protein.
(A) Immunoblotting of EZH2, ZRANB1, and GAPDH in MDA-MB-231 cells
transfected with ZRANB1 siRNA or a scramble control (Scr). (B) Immunoblotting
of EZH2, H3K27me3, H3, and FLAG-ZRANB1 in HEK293T cells transfected with
SFB-ZRANB1 and ZRANB1 siRNA, alone or in combination. (C) qPCR of EZH2
and ZRANB1 in LM2 cells transfected with ZRANB1 siRNA or a scramble control.
n = 3 biological replicates. (D) qPCR of EED, RBBP4, and SUZ12 in LM2 cells
transfected with ZRANB1 siRNA or a scramble control. n = 3 biological
replicates. (E) Immunoblotting of EZH2, SUZ12, EED, ZRANB1, H3K27me1,
H3K27me2, H3K27me3, H3, and β-actin in two independent clones of ZRANB1knockout HEK293A cells generated by CRISPR-Cas9. Error bars in (C) and (D)
are s.e.m. These experiments were done by Dr. Peijing Zhang.
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To demonstrate whether ZRANB1 directly regulates EZH2, we performed
an in vitro binding assay using purified His-ZRANB1 and purified GST-EZH2 and
found that His-ZRANB1 could bind to GST-EZH2 under cell-free condition
(Figure 5A), suggesting that ZRANB1 may directly regulate EZH2. Furthermore,
we observed the interaction of ZRANB1 with endogenous EZH2 and SUZ12
(Figure 5B), and reciprocally, the interaction of either exogenous (Figure 5C) or
endogenous (Figure 5D) EZH2 with endogenous ZRANB1, SUZ12, and EED,
suggesting that ZRANB1 may regulate EZH2 that is present in the PRC2
complex.
We then examined the expression of 10 previously reported PRC2 target
genes and found that ADRB2 and DAB2IP were significantly upregulated by
knockdown of EZH2 in MDA-MB-231 cells (Figure 6A); consistently, knockdown
of ZRANB1 in MDA-MB-231 cells also increased ADRB2 and DAB2IP mRNA
levels (Figure 6B). Moreover, we performed RNA-Seq analysis to compare the
effect of ZRANB1 and EZH2 on global gene expression. A total of 63 genes,
including known EZH2 targets or downstream genes SERPINB2 (104), PTGS2
(encoding cyclooxygenase-2) (105), ABCA1 (106), and MMP9 (107), were
differentially expressed (49 upregulated and 14 downregulated) by at least 1.6fold (P < 0.05) upon knockdown of either ZRANB1 or EZH2 in LM2 cells (Figures
6C and 6D; Table 4). Taken together, our data suggest that ZRANB1 is a
functional regulator of EZH2.
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Figure 5. ZRANB1 directly binds to EZH2.
(A) Left panel: purified GST-EZH2 was incubated with purified His-ZRANB1,
followed by pulldown with nickel beads and immunoblotting with antibodies
against EZH2 and ZRANB1. Right panel: purified recombinant proteins were
analyzed

by

SDS-PAGE

and

Coomassie

blue

staining.

(B)

Co-

immunoprecipitation of endogenous EZH2 with endogenous ZRANB1, SUZ12,
and EED. EZH2 was immunoprecipitated from HEK293T cells, followed by
immunoblotting with antibodies against ZRANB1, EZH2, SUZ12, and EED. (C)
HEK293T cells were transfected with SFB-GFP or SFB-ZRANB1, followed by
pulldown with S-protein beads and immunoblotting with antibodies against EZH2,
SUZ12, and FLAG. (D) LM2 cells were transduced with MYC-EZH2, followed by
immunoprecipitation with anti-MYC beads and immunoblotting with antibodies
against ZRANB1, EZH2, SUZ12, and EED.
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Figure 6. ZRANB1 is a functional regulator of EZH2.
(A, B) qPCR of ADRB2 and DAB2IP in MDA-MB-231 cells transduced with EZH2
shRNA (A) or transfected with ZRANB1 siRNA (B). Error bars are s.e.m. P
values were calculated from a two-tailed t-test. (C) Heatmap of 63 genes that
were identified by RNA-Seq analysis to be commonly upregulated (49 genes) or
downregulated (14 genes) in ZRANB1-knockdown and EZH2-knockdown LM2
cells. Genes are shown in rows and samples are shown in columns. (D) Venn
diagrams of all genes that were identified by RNA-Seq analysis to be upregulated
or downregulated in ZRANB1-knockdown (blue) or EZH2-knockdown (pink) LM2
cells. Threshold values in (C) and (D): corrected P value < 0.05 and absolute
log2 fold change (log2FC) > 0.7. Additional information is available in Table 4. n
= 3 samples per group for (A-D). Dr. Peijing Zhang performed (A) and (B). RNASeq analysis was performed in collaboration with Mutian Zhang.
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Table 4. Differentially expressed genes upon knockdown of ZRANB1 or
EZH2 in LM2 cells.
Gene
MMP9
CXCL8
MMP1
CA9
TNFSF15
SERPINB2
INHBA
ADAMTS9
PTGS2
PDE1C
PODXL2
PADI4
MMP3
BCL2A1
ANXA10
ICAM1
PMEPA1
DNER
BMF
SIRPB1
TNFAIP3
ANGPTL4
LYPD3
SLX1ASLX1BSULT1A4
OTUB2
PPP4R4
PTPRB
TGFBR1
TMEM2
CPM
L1CAM
ICOSLG

LogFC_
SCvsZR
inf
6.079
5.389
4.742
4.711
3.773
3.708
3.699
3.648
3.639
3.531
3.389
3.351
3.169
3.163
2.738
2.640
2.631
2.607
2.593
2.564
2.438
2.041

LogFC_
CTvsEZ
0.759
1.316
3.608
0.773
1.260
1.006
0.873
0.788
1.005
0.743
1.431
1.989
1.436
0.867
1.479
0.824
0.800
0.950
0.702
1.015
1.149
0.733
1.263

RORA
ERN1
NOG
GPRC5B
NR4A1
ADTRP
GLUL
FZD8
CCND2
GPR37
SYT1
VIPR1
SEMA3D
COL4A5
ABCA1
DDIT4L
PGM2L1
LLGL2
LDHD
LZTS1
NLRP2
JAG2
NKX6-1

LogFC_
SCvsZR
1.270
1.154
1.102
1.047
1.036
1.017
1.013
0.944
0.938
0.910
0.864
0.814
0.799
0.796
0.773
0.751
0.731
-1.402
-1.313
-0.886
-0.860
-0.833
-0.820

LogFC_
CTvsEZ
0.871
0.701
0.927
1.120
1.062
0.798
1.773
0.756
1.819
0.714
0.923
1.150
0.894
0.777
1.072
0.937
0.983
-0.803
-1.210
-0.736
-1.202
-1.276
-0.907

1.916

1.449

MTL5

-0.785

-0.800

1.878
1.522
1.463
1.368
1.323
1.321
1.308
1.305

0.728
0.825
1.230
0.900
0.770
0.743
1.019
0.958

ELF3
IFT27
CDKN1C
MX1
NRARP
CCNA1
TMEM163

-0.783
-0.765
-0.761
-0.747
-0.725
-0.706
-0.702

-1.025
-0.807
-0.726
-0.752
-0.931
-1.184
-1.022

Gene
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3.2.2 ZRANB1 is an EZH2 deubiquitinase
To determine whether ZRANB1 stabilizes EZH2 protein, we first examined
the levels of ectopically expressed EZH2 protein in HEK293T cells in the
presence of cycloheximide (CHX), an inhibitor of protein synthesis. As expected,
overexpression of ZRANB1 led to a prominent increase in the basal level and
half-life of EZH2 protein, whereas the level and stability of co-transfected GFP
were not affected (Figures 7A and 7B). To determine whether ZRANB1
regulates the half-life of endogenous EZH2 protein, we transiently transfected
LM2 cells with ZRANB1 siRNA and treated cells with CHX; we found that
knockdown of ZRANB1 in LM2 cells markedly shortened the half-life of
endogenous EZH2 (Figures 7C and 7D).
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Figure 7. ZRANB1 regulates EZH2 protein stability.
(A) HEK293T cells were co-transfected with MYC-EZH2, MYC-GFP, and SFBZRANB1, treated with 50 µg ml-1 cycloheximide (CHX), harvested at different
time points, and then immunoblotted with antibodies against MYC and FLAG.
MYC-GFP served as the control for transfection. (B) Quantification of EZH2
protein levels (normalized to MYC-GFP) in (A). (C) LM2 cells were transfected
with ZRANB1 siRNA, treated with 50 µg ml-1 CHX, harvested at different time
points, and then immunoblotted with antibodies against EZH2 and β-actin. (D)
Quantification of EZH2 protein levels (normalized to β-actin) in (C). Dr. Peijing
Zhang performed (A).
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We reasoned that ZRANB1 stabilizes EZH2 through deubiquitination.
Indeed, we compared the EZH2 polyubiquitination of ZRANB1-knockout
HEK293A cells and control HEK293A cells and found that knockout of ZRANB1
by

gRNA

increased

EZH2

ubiquitination

(Figure

8A).

Conversely,

overexpression of ZRANB1 in ZRANB1-knockout HEK293A cells substantially
reduced EZH2 polyubiquitination (Figure 8B). To further determine whether
ZRANB1 directly deubiquitinates EZH2, we incubated purified ZRANB1 and
ubiquitinated EZH2 purified from ZRANB1-knockout HEK293A cells in a cell-free
system. ZRANB1 purified from insect cells markedly decreased EZH2
polyubiquitination in vitro (Figure 8C), suggesting that EZH2 is a direct substrate
of ZRANB1. Previous studies have revealed that ZRANB1 preferentially cleaves
K29-, K33-, and K63-linked polyubiquitin chains (108-110). Using all seven
lysine-specific mutants of ubiquitin (e.g., the K33 mutant contains only a single
lysine, K33, with all other six lysines mutated to arginine), we found that
ZRANB1-knockout cells showed upregulation of K33-linked, but not other lysinelinked, polyubiquitination of EZH2 (Figure 8D); moreover, purified ZRANB1
strongly deubiquitinated K33-linkage specific ubiquitinated EZH2 in vitro (Figure
8E).
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Figure 8. ZRANB1 regulates EZH2 ubiquitination.
(A) Control and ZRANB1-knockout HEK293A cells were co-transfected with
MYC-EZH2 and HA-ubiquitin (Ub), followed by immunoprecipitation with antiMYC beads and immunoblotting with antibodies against HA and EZH2. (B)
ZRANB1-knockout HEK293A cells were co-transfected with MYC-EZH2 and
SFB-ZRANB1, followed by immunoprecipitation with anti-MYC beads and
immunoblotting with antibodies against Ub and MYC. (C) Ubiquitinated MYCEZH2 was purified with anti-MYC beads from ZRANB1-knockout HEK293A cells
co-transfected with MYC-EZH2 and HA-Ub, and was incubated with His-ZRANB1
purified from insect cells. After the in vitro deubiquitination reaction, the bound
proteins were eluted by boiling in Laemmli sample buffer and immunoblotted with
antibodies against HA and EZH2. (D) Control and ZRANB1-knockout HEK293A
cells were co-transfected with MYC-EZH2 and lysine-specific mutants of HA-Ub,
followed by immunoprecipitation with anti-HA beads and immunoblotting with
antibodies against EZH2 and HA. (E) K33-linkage specific ubiquitinated MYCEZH2 was purified with anti-MYC beads from ZRANB1-knockout HEK293A cells
co-transfected with MYC-EZH2 and the K33-specific mutant of HA-Ub, and was
incubated with His-ZRANB1 purified from insect cells. After the in vitro
deubiquitination reaction, the bound proteins were eluted by boiling in Laemmli
sample buffer and immunoblotted with antibodies against HA and EZH2. These
experiments were performed in collaboration with Dr. Peijing Zhang.
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ZRANB1 consists of three N-terminal zinc finger (NZF) domains, a central
ankyrin repeat ubiquitin-binding domain (AnkUBD), and a C-terminal OTU
domain (110). Deletion analysis using various truncation mutants (M1: NZFs; M2:
NZFs + AnkUBD; M3: AnkUBD + OTU; Figure 9A) demonstrated that the OTU
domain mediated the physical interaction of ZRANB1 with EZH2 (Figure 9B).
Importantly, both the full length ZRANB1 and its M3 mutant (AnkUBD + OTU),
but not the M1 (NZFs) or M2 (NZFs + AnkUBD) mutants, strongly elevated EZH2
protein levels, suggesting that OTU domain is required for the stabilization of
EZH2 by ZRANB1 (Figure 9C). Consistent with a previous report (61), we
observed both nuclear and cytoplasmic expression of ZRANB1 (Figure 9D), as
well as its co-localization with EZH2 in the nucleus (Figure 9E). It should be
noted that all three truncation mutants of ZRANB1 were also localized in both the
nucleus and the cytoplasm (Figure 9D), suggesting that the M1 and M2 mutants
of ZRANB1 did not interact with EZH2 because they lack the OTU domain, not
because they were not localized in the nucleus. Therefore, the OTU domain of
ZRANB1 is a functional domain in regulating EZH2.
As reported previously (59), EZH2 consists of EID domain (EED interaction
domain), D1 domain (homologous domain 1), D2 domain (homologous domain
2), CXC domain (cysteine-rich domain) and SET domain (SU(var)3-9, E(z) and
Trithorax histone methyltransferase domain). To determine which domain of
EZH2 is critical for interacting with ZRANB1, we transiently transfected HEK293T
cells with HA-ZRANB1 and SFB-tagged full-length EZH2 or its various deletion
mutants (Figure 10A), followed by immunoprecipitation with anti-HA beads. This
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binding-domain mapping analysis showed that the CXC domain of EZH2 could
interact with ZRANB1 (Figure 10B). To further determine whether CXC domain
of EZH2 is the only part responsible for the interaction, we generated the CXC
domain deletion mutant (EZH2 ΔCXC, with aa 502-618 deleted, Figure 10C) and
performed the binding-domain mapping assay. It should be noted that both the
full length EZH2 and its ΔCXC mutant could bind to ZRANB1 (Figure 10D),
indicating that CXC domain is sufficient but not necessary for its interaction with
ZRANB1. To identify the other binding domain, we performed the binding domain
mapping assay using the N-terminal region (EID + D1, aa 1-159) and the D2
domain fragment (aa 218-334), and found that the N-terminal region (EID + D1)
was able to bind ZRANB1 (Figures 10E and 10F). Collectively, both the Nterminal region (EID + D1) and the CXC domain of EZH2 could interact with
ZRANB1.
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Figure 9. ZRANB1 interacts with and stabilizes EZH2 through OTU domain.
(A) Schematic diagram of full-length (FL) ZRANB1 and its deletion mutants. (B)
HEK293T cells were co-transfected with equal amounts of MYC-EZH2 and SFBtagged FL ZRANB1 or its mutants, followed by pulldown with S-protein beads
and immunoblotting with antibodies against MYC and FLAG. (C) HEK293T cells
were co-transfected with MYC-EZH2, MYC-GFP, and SFB-tagged FL ZRANB1
or its mutants, followed by immunoblotting with antibodies against MYC and
FLAG. (D) Immunoblotting of FLAG-ZRANB1, Vinculin (cytoplasmic marker), and
Lamin A/C (nuclear marker) in cytoplasmic and nuclear fractions of HEK293T
cells

transfected

with

SFB-tagged

FL

ZRANB1

or

its

mutants.

(E)

Immunofluorescent staining of ZRANB1 (green) and EZH2 (red) in HEK293T
cells co-transfected with SFB-ZRANB1 and MYC-EZH2. Scale bars, 10 µm.
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Figure 10. N-terminal region (EID + D1) and CXC domain of EZH2 interact
with ZRANB1.
(A) Schematic diagram of full-length EZH2 protein and its various deletion
mutants. (B) HEK293T cells were co-transfected with HA-ZRANB1 and FLAGtagged full-length EZH2 or its deletion mutants, followed by immunoprecipitation
with anti-HA beads and immunoblotting with antibodies against FLAG and HA.
(C) Schematic diagram of full-length EZH2 protein and its ΔCXC mutant. (D)
HEK293T cells were co-transfected with HA-ZRANB1 and FLAG-tagged fulllength EZH2 or the ΔCXC mutant, followed by immunoprecipitation with anti-HA
beads and immunoblotting with antibodies against FLAG and HA. (E) Schematic
diagram of full-length EZH2 protein and its fragment mutants. (F) HEK293T cells
were co-transfected with HA-ZRANB1 and FLAG-tagged full-length EZH2, EID +
D1 fragment, or D2 fragment, followed by immunoprecipitation with anti-HA
beads and immunoblotting with antibodies against FLAG and HA. Dr. Yutong
Sun performed (B).
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3.2.3 ZRANB1 is a cancer-promoting deubiquitinase and a potential
therapeutic target
Whereas EZH2 has been shown to promote mammary tumorigenesis and
metastasis (81, 83, 85, 86, 89, 90, 111), the function of ZRANB1 in cancer is
unknown. To determine the biological function of ZRANB1 in TNBC, we
transfected two independent ZRANB1 siRNAs (#2 and #5) into MDA-MB-231
cells and found that both siRNAs drastically inhibited cell proliferation (Figure
11A) and migration (Figure 11B). siRNA-mediated knockdown of ZRANB1 also
led to EZH2 downregulation and proliferative deficiency in nine additional TNBC
cell lines: BT549, SUM149, SUM159, SUM229, MDA-MB-157, MDA-MB-436,
MDA-MB-468, HCC1806, and Hs578T (Figures 11C-11E), indicating that
depletion of ZRANB1 generally leads to EZH2 downregulation and inhibits cell
proliferation in TNBC cell lines. Importantly, re-expression of ZRANB1 rescued
the inhibitory effect of ZRANB1 siRNA (Figures 12A and 12B) and ZRANB1
gRNA (Figures 12C and 12D) on EZH2 protein levels and cell proliferation.

56

57

Figure 11. ZRANB1 is a growth-promoting deubiquitinase in TNBC.
(A) Growth curves of MDA-MB-231 cells transfected with ZRANB1 siRNA or a
scramble control. n = 3 biological replicates. (B) Transwell migration assays of
MDA-MB-231 cells transfected with ZRANB1 siRNA or a scramble control. Cells
were stained 18 hours after seeding. (C) qPCR of ZRANB1 in nine TNBC cell
lines transfected with ZRANB1 siRNA or a scramble control. n = 3 biological
replicates. (D) Immunoblotting of EZH2 and β-actin in nine TNBC cell lines
transfected with ZRANB1 siRNA or a scramble control. (E) Growth curves of nine
TNBC cell lines transfected with ZRANB1 siRNA or a scramble control. Cells
were seeded in 6-well plates. n = 3 biological replicates. Error bars in (A), (C)
and (E) are s.e.m. P values were calculated from a two-tailed t-test. (A) and (B)
were performed by Dr. Peijing Zhang.
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Figure 12. Re-expression of ZRANB1 rescues the inhibitory effect of
ZRANB1 siRNA and gRNA.
(A and B) HEK293T cells were transfected with ZRANB1 siRNA and SFBZRANB1, alone or in combination. 24 hours after transfection, cells were
harvested for immunoblotting with antibodies against EZH2, β-actin, and FLAG
(A), and the remaining cells were seeded in 24-well plates for growth curves (B).
n = 3 biological replicates in (B). (C) Immunoblotting of EZH2, ZRANB1, and
HSP90 in control, ZRANB1-knockout, and ZRANB1-restored HEK293A cells. (D)
Growth curves of control, ZRANB1-knockout, and ZRANB1-restored HEK293A
cells. n = 3 biological replicates. Error bars in (B) and (D) are s.e.m. P values
were calculated from a two-tailed t-test. These experiments were performed by
Dr. Peijing Zhang.
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We next asked whether EZH2 is a functional effector of ZRANB1. First, we
transduced control and EZH2 shRNA in LM2 cells and then transiently
transfected SFB-ZRANB1. Ectopic expression of ZRANB1 in LM2 cells (Figures
13A and 13B) markedly upregulated endogenous EZH2 protein and increased
cell proliferation, which could be reversed by knockdown of EZH2. Conversely,
we generated LM2 cells stably overexpressing endogenous-comparable levels of
MYC-EZH2 protein and then silenced ZRANB1 expression using ZRANB1
siRNA. Depletion of ZRANB1 in LM2 cells (Figures 13C and 13D) markedly
downregulated endogenous EZH2 pqarotein and inhibited cell proliferation, which
could be reversed by ectopic expression of EZH2. To further investigate whether
catalytically inactive mutant of EZH2 could rescue ZRANB1 siRNA-induced
growth defect, we generated the catalytically dead mutant (EZH2 ΔSET, with aa
618-751 deleted) and assessed its effects on the proliferation of MDA-MB-231
cells. Expression of either wild-type EZH2 or the catalytically inactive mutant
(ΔSET) largely rescued ZRANB1 siRNA-induced growth defect (Figures 13E and
13F), underscoring the importance of EZH2’s non-catalytic function. Taken
together, ZRANB1 is a growth-promoting deubiquitinase, and its function is
mediated, at least in part, by its substrate EZH2.
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Figure 13. ZRANB1 promotes growth through EZH2.
(A and B) LM2 cells were transduced with EZH2 shRNA or a scramble control,
and were then transfected with SFB-ZRANB1. 24 hours after transfection, cells
were harvested for immunoblotting with antibodies against EZH2, FLAG, and βactin (A) or seeded in 24-well plates for growth curves (B). (C) Immunoblotting of
EZH2 and β-actin in control and MYC-EZH2-transduced LM2 cells with or without
ZRANB1 siRNA transfection. (D) Growth curves of control and MYC-EZH2transduced LM2 cells with or without ZRANB1 siRNA transfection. (E and F)
ZRANB1 siRNA-transfected MDA-MB-231 cells were transfected with SFBtagged full-length EZH2 (FL) or its mutant (ΔSET), and were then harvested for
immunoblotting with antibodies against EZH2, FLAG, and β-actin (E) or seeded
in 6-well plates for growth curves (F). In (B), (D) and (F), n = 3 biological
replicates. Error bars are s.e.m. P values were calculated from a two-tailed t-test.
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To determine whether inhibition of ZRANB1 has anticancer effects in vivo,
we incorporated ZRANB1 siRNA or a scramble control into the neutral
nanoliposome, 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), which can
remain in animal issues for at least 48 hours without detectable toxicity (112) and
has been used to deliver siRNA or miRNA oligonucleotides to tumor-bearing
mice (64, 65). We implanted luciferase-expressing LM2 cells into the mammary
fat pads of NSG (non-obese diabetic; severe combined immunodeficiency;
interleukin-2 receptor gamma chain null) mice. Three days after tumor cell
implantation, we confirmed the initial tumor establishment by bioluminescent
imaging, excluded the outliers, and randomly divided the mice into four treatment
groups: (1) vehicle (PBS); (2) scramble-DOPC; (3) si-ZRANB1#2-DOPC; and (4)
si-ZRANB1#5-DOPC. The treatment was administered through the tail vein twice
weekly at a dose of 250 µg kg-1 body weight. At 4 weeks, the average tumor
volumes in the two ZRANB1 siRNA treatment groups were 276.9 mm3 and 231.8
mm3, respectively, which was approximately 60% less than those in the vehicle
group (674 mm3) and the scramble-DOPC group (692.7 mm3; Figure 14A).
Similarly, the two independent ZRANB1 siRNAs also reduced tumor weight by
approximately 60% (Figure 14B). As anticipated, EZH2 protein in the tumor was
markedly downregulated in the two ZRANB1 siRNA treatment groups compared
with both the vehicle group and the scramble control group (Figure 14C),
demonstrating that in vivo delivery of ZRANB1 siRNA was effective in
destabilizing EZH2.
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To assess the effect of ZRANB1 inhibition on lung metastatic colonization, we
injected LM2 cells into NSG mice through the tail vein and then used the same
dosage regimen as in the tumor growth study. Using a human ZRANB1-specific
TaqMan assay, we found that systemic treatment with the two ZRANB1 siRNAs
decreased human ZRANB1 mRNA levels in lung issues by 60% and 73%,
respectively, compared with the scramble control group (Figure 14D).
Bioluminescent imaging of live animals revealed consistent reduction of lung
metastases in mice treated with DOPC-encapsulated ZRANB1 siRNA, but not in
mice treated with DOPC-encapsulated scramble RNA oligonucleotides (Figures
14E and 14F). At week 5, the si-ZRANB1#2-DOPC group and the si-ZRANB1#5DOPC group exhibited a 55% and 86% reduction, respectively, in lung
metastases relative to the vehicle group, whereas the scramble-DOPC group
showed no significant difference from the vehicle group (Figures 14F and 14G).
Collectively, delivery of nanoliposomal ZRANB1 siRNA led to marked antitumor
and antimetastatic effects in this TNBC model.
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Figure 14. Depletion of ZRANB1 leads to antitumor and antimetastatic
effects.
(A and B) Tumor growth curves (A) and tumor weight (at week 4, B) of NSG
mice with mammary fat pad injection of LM2 cells. From day 3, mice received
twice weekly intravenous injection of the vehicle, DOPC-encapsulated ZRANB1
siRNA, or scramble oligonucleotides. n = 3 (the vehicle group) or 5 (all other
groups) mice per group. (C) Immunoblotting of EZH2 and β-actin in tumor lysates
from the mice described in (A) and (B). n = 3 mice per group. (D) qPCR of
human-specific ZRANB1 in lung tissues from NSG mice with tail vein injection of
LM2 cells. From day 3, mice received twice weekly intravenous injection of the
vehicle, DOPC-encapsulated ZRANB1 siRNA, or scramble oligonucleotides. n =
5 mice per group. (E and F) Bioluminescent imaging (E) and quantification of
photon flux (F) of the mice described in (D). n = 6 mice per group at the time of
the first treatment; n = 5 or 6 mice per group at the end point. (G) H&E staining of
lungs isolated from the mice described in (D). Scale bar, 500 µm. Error bars in
(A), (B), (D), and (F) are s.e.m. P values were calculated from a two-tailed t-test.
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3.2.4 A ZRANB1 inhibitor destabilizes EZH2 and inhibits cell viability
through ZRANB1
Although the function of ZRANB1 in cancer was not reported before, Wu
and colleagues searched for compounds in the National Cancer Institute (NCI)
database that potentially bind to ZRANB1’s catalytic site based on the crystal
structure of the OTU domain (56). Then 125 compounds that stood out in the in
silico screen were tested for their ability to inhibit the cleavage of K63-linked
hexa-ubiquitin by ZRANB1 in vitro. Two of them, NSC112200 and NSC267309,
blocked ZRANB1’s deubiquitinase activity at 10 µM, whereas a compound with
the similar chemical structure, NSC60650, showed no inhibition even at 30 µM
(56).
NSC112200 is a mixture of 2,5-dibromo-3,6-dimethyl-1,4-benzenediol and
2,5-dibromo-3,6-dimethyl-1,4-benzoquinone

(56),

which

we

confirmed

by

ultrahigh pressure liquid chromatography-mass spectrometry (UPLC-MS) and
nuclear magnetic resonance (NMR) analysis. In an in vitro deubiquitination assay
using ubiquitin chains as substrates, we found that ZRANB1 cleaved K33-linked
di-ubiquitin; this cleavage was blocked by NSC112200, but not by the control
compound, NSC60650 (1,5-dichloro-2,4-dihydroxybenzene) (56) (Figure 15A).
We also found that NSC112200 inhibited the deubiquitinase activity of ZRANB1,
but not another OTU family member A20 (Figure 15B). These in vitro DUB
activity assays suggest that NSC112200 can directly act on ZRANB1.
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Figure 15. NSC112200 destabilizes EZH2 and inhibits cell viability.
(A) Purified His-ZRANB1 was pretreated with NSC60650 or NSC112200 for 10
minutes and then incubated with K33-linked di-ubiquitin in the presence of the
compound at 37ºC for 1.5 hours. Samples were then analyzed by immunoblotting
with a ubiquitin-specific antibody. (B) Purified ZRANB1 or A20 was pretreated
with NSC112200 for 10 minutes and then incubated with K63-linked tetraubiquitin in the presence of NSC112200 at 37ºC for 1.5 hours. Samples were
then analyzed by immunoblotting with a ubiquitin-specific antibody. (C)
Immunoblotting of EZH2 and β-actin in LM2 cells treated with NSC112200 at the
indicated doses for 24 hours. (D) LM2 cells were treated with NSC112200 at the
indicated doses. 24 hours after treatment, viable cells were quantitated by an
MTT assay. n = 4 biological replicates. (E) qPCR of EZH2 in BT549 and LM2
cells treated with 10 µM NSC112200. n = 3 biological replicates. (F)
Immunoblotting of EZH2 and β-actin in BT549 cells treated with NSC112200 at
the indicated doses for 24 hours. (G) BT549 cells were treated with NSC112200
at the indicated doses. 24 hours after treatment, viable cells were quantitated by
an MTT assay. n = 4 biological replicates. (H and I) Immunoblotting of EZH2,
SUZ12, and β-actin in LM2 (H) and BT549 (I) cells treated with NSC60650 or
NSC112200 at the indicated doses for 24 hours. Dr. Peijing Zhang performed (A)
and (B).
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We asked whether NSC112200 regulates EZH2 and cell viability in TNBC
cells. Indeed, treatment of LM2 cells (which are resistant to GSK126, Figure 2C)
with NSC112200 downregulated EZH2 protein and inhibited cell viability in a
dose-dependent manner (Figures 15C and 15D), without significantly altering
mRNA levels of EZH2 (Figure 15E); similar effects were also observed in BT549
cells (Figures 15F and 15G). In contrast, treatment of LM2 and BT549 cells with
NSC60650, which has the similar chemical structure but does not inhibit
ZRANB1’s deubiquitinase activity (56) (Figure 15A), had little or no effect on
EZH2 protein level and cell viability (Figures 15D, 15G, 15H, and 15I).
We further assessed the dependence of NSC112200-induced EZH2
downregulation and cell death on ZRANB1 and the ubiquitin-proteasome system.
Treatment with the proteasome inhibitor MG132 abolished the downregulation of
EZH2 by NSC112200 (Figure 16A), suggesting that NSC112200 promotes
proteasomal degradation of EZH2. Indeed, treatment with NSC112200 markedly
increased the ubiquitination of EZH2 (Figure 16B) and decreased its half-life
(Figure 16C), which recapitulated the effects of ZRANB1 genetic depletion.
Importantly, NSC112200 treatment downregulated EZH2 protein in HEK293A
cells transfected with control gRNA, but not in isogenic ZRANB1-knockout
HEK293A cells (Figures 16D and 16E), indicating that this compound
destabilizes EZH2 through ZRANB1. Moreover, we assessed the viability of
NSC112200-treated ZRANB1-knockout HEK293A cells and found that they were
much more resistant to NSC112200 than isogenic ZRANB1 wild-type cells; reexpression of ZRANB1 in these ZRANB1-knockout cells restored their sensitivity
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to NSC112200 (Figure 16F). Collectively, these data suggest that inhibition of
ZRANB1 may selectively kill cells with abundant ZRANB1 and EZH2 expression.
It should be noted that Zranb1-null mice had normal development and
growth (61), and that tissues from these mutants showed a marginal decrease or
no change in Ezh2 protein levels (Figure 17A), suggesting that normal cells are
not dependent on ZRANB1. One possibility could be low expression of ZRANB1
in normal cells. Indeed, in the normal human mammary epithelial cell lines
MCF10A and HMLE, which showed undetectable ZRANB1 protein (Figure 17B),
ZRANB1 siRNA or NSC112200 treatment had no effect on EZH2 and little effect
on cell proliferation and viability (Figures 17C-17G). Similarly, knockdown of
Zranb1 by siRNA (#5) did not affect mouse embryonic fibroblast (MEF)
proliferation (Figures 17H and 17I). Furthermore, normal C57/BL6 mice treated
with DOPC-encapsulated ZRANB1 siRNA (#5) showed no significant changes in
survival, behavior, body weight, or liver weight (Figures 17J and 17K). Livers
from all three treatment groups (vehicle, scramble, and ZRANB1 siRNA)
exhibited no necrosis, fibrosis, steatosis, or biliary changes (Figure 17L). Taken
together, these data demonstrated the safety of ZRANB1 depletion or inhibition
in normal tissues.
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Figure 16. NCS112200 destabilizes EZH2 and inhibits cell viability through
ZRANB1 and ubiquitin-proteasome system.
(A) Immunoblotting of EZH2 and β-actin in LM2 cells pretreated with 2 µM
MG132 for 1 hour and then treated with 10 µM NSC112200 in the presence of
MG132 overnight. (B) HEK293T cells were co-transfected with MYC-EZH2 and
HA-ubiquitin (Ub), pretreated with 2 µM MG132 for 1 hour, and then treated with
10 µM NSC112200 in the presence of MG132 overnight, followed by
immunoprecipitation with anti-MYC beads and immunoblotting with antibodies
against HA and EZH2. N.S.: non-specific signal. (C) Upper panel: LM2 cells were
pretreated with 10 µM NSC112200, treated with 50 µg ml-1 CHX in the presence
of NSC112200, harvested at different time points, and then immunoblotted with
antibodies against EZH2 and β-actin. Lower panel: quantification of EZH2 protein
levels (normalized to β-actin). (D) Immunoblotting of EZH2 and β-actin in control
and ZRANB1-knockout HEK293A cells treated with 10 µM NSC112200
overnight. Right panel: quantification of EZH2 protein levels (normalized to βactin). (E) Quantification of EZH2 protein levels in (D) (normalized to β-actin). (F)
Control, ZRANB1-knockout, and ZRANB1-restored HEK293A cells were treated
with 10 µM NSC112200 for 24 hours, and viable cells were quantitated by an
MTT assay. Data are normalized to vehicle-treated cells for each group. n = 4
biological replicates. Error bars are s.e.m. P values were calculated from a twotailed t-test. Dr. Peijing Zhang performed (A), (B), and (D).
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Figure 17. Effects of ZRANB1 depletion or inhibition on normal cells and
mice.
(A) Immunoblotting of EZH2 and β-actin in tissues from Zranb1+/+ (WT) and
Zranb1-/- (KO) mice. (B) Immunoblotting of ZRANB1 and β-actin in LM2, MDAMB-231, BT549, MCF10A, and HMLE cells. (C) Immunoblotting of ZRANB1,
EZH2 and β-actin in MDA-MB-231, MCF10A, and HMLE cells transfected with
ZRANB1 siRNA. SE: short exposure; LE: long exposure. (D and E) Growth
curves of MCF10A (D) and HMLE (E) cells transfected with ZRANB1 siRNA or a
scramble control. n = 3 biological replicates. (F) Immunoblotting of EZH2, SUZ12,
and β-actin in MCF10A cells treated with NSC60650 or NSC112200 at the
indicated doses for 24 hours. (G) MCF10A cells were treated with NSC112200 at
the indicated doses. 24 hours after treatment, viable cells were quantitated by an
MTT assay. n = 4 biological replicates. (H) qPCR of Zranb1 in MEF cells
transfected with ZRANB1 siRNA or a scramble control. n = 3 biological
replicates. (I) Growth curves of MEF cells transfected with ZRANB1 siRNA or a
scramble control. n = 3 biological replicates. (J and K) Total body weight
(measured twice a week, J) and liver weight (measured post-mortem, K) of
normal C57BL/6 mice that received twice weekly intravenous injection of the
vehicle, DOPC-encapsulated ZRANB1 siRNA (#5), or scramble oligonucleotides.
n = 5 mice per group. (L) H&E staining of livers isolated from the mice described
in (J). Scale bar, 50 µm. Error bars in (D), (E), (H), (I), (J), and (K) are s.e.m. P
values were calculated from a two-tailed t-test.
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3.2.5 ZRANB1 levels correlate with EZH2 levels and poor survival in human
breast cancer
To address whether the regulation of EZH2 by ZRANB1 is relevant in
human cancer, we performed immunohistochemical staining of these two
proteins on human breast tumor tissue microarrays (125 cases were TNBC and
83

cases

were

non-TNBC).

Consistent

with

fractionation

assays

and

immunofluorescent staining of cell lines (Figures 9D and 9E), ZRANB1 protein
was localized in both the nucleus and the cytoplasm in primary tumor tissues,
whereas EZH2 protein was found only in the nucleus (Figure 18A). Notably, 67%
(106 of 158) of the tumors with low ZRANB1 expression exhibited low EZH2
expression, and 84% (42 of 50) of the tumors with high ZRANB1 expression
showed high EZH2 expression (Spearman correlation R = 0.44, P < 1 × 10-6,
Figure 18B). We also plotted the EZH2 protein score versus the ZRANB1 protein
score for individual patients, which revealed a highly significant correlation (linear
regression R2 = 0.49, P < 1 × 10-6, Figure 18C).
To evaluate whether high ZRANB1 expression is associated with poor clinical
outcomes, we performed immunohistochemical staining of ZRANB1 on 138
tumor tissue specimens from breast cancer patients (23 cases were TNBC) with
a long-term (~10 years) follow-up record. Kaplan-Meier analysis showed that
patients with high levels of ZRANB1 protein had shorter overall survival than
patients with low levels of ZRANB1 (HR = 2.6, P = 0.01, Figure 18D). Finally,
analysis of The Cancer Genome Atlas (TCGA) data revealed amplifications (at
10q26.13, Figure 18E) or missense mutations of the ZRANB1 gene in a subset
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of breast cancer and ovarian cancer. It is possible that additional mechanisms
also contribute to ZRANB1 alternations in human tumors, which warrants future
investigation.
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Figure 18. ZRANB1 levels correlate with EZH2 levels and poor survival in
human breast cancer.
(A) Immunohistochemical staining of ZRANB1 and EZH2 in representative breast
tumor specimens. Scale bar, 50 µm. (B) Correlation between ZRANB1 and EZH2
protein levels in human breast tumors. The P value was calculated from a chisquare test. R is the Spearman correlation coefficient. (C) ZRANB1 protein
scores (X-axis) in primary breast tumors positively correlate with EZH2 protein
scores (Y-axis) in individual patients. The P value was calculated from a linear
regression analysis. R is the correlation coefficient. Protein score = the
percentage of immunopositive cells × immunostaining intensity. (D) Kaplan-Meier
curves of overall survival of breast cancer patients (n = 138 patients), stratified by
ZRANB1 protein levels. Protein score = the percentage of immunopositive cells ×
immunostaining intensity. High or low protein expression was defined using the
mean score of all samples as a cutoff point. The P value was calculated from a
log-rank test. HR is the hazard ratio. (E) The amplification peak containing
ZRANB1 in breast cancer and ovarian cancer (TCGA cohorts). Dr. Yongkun Wei
performed IHC staining and Dr. Yumeng Wang performed the TCGA data
analysis.
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3.3 Discussion
EZH2 is mutated or highly expressed in many cancer types. Experimentally,
genetically engineered mouse models have provided strong evidence that EZH2
drives or accelerates oncogenesis in lymphoma (87, 88, 91), melanoma (91),
breast cancer (89, 90), and lung cancer (113). Previous studies mainly attributed
the cancer-promoting function of EZH2 to the repression of PRC2 target genes
through H3K27me3-mediated epigenetic silencing (114). However, more recent
studies have demonstrated that the non-catalytic function of EZH2 contributes
substantially to tumor formation and progression (97, 98, 100, 101). On the one
hand, EZH2 is reported to stabilize the PRC2 complex independently of its
catalytic activity (97). On the other hand, EZH2 may function as a transcription
activator or coactivator in a polycomb- and methylation-independent manner to
directly induce the transcription of several genes, such as c-Myc, Cyclin D1 (100,
115), and the target genes of androgen receptor (AR) (99), NF-κB (101), and βcatenin (59).
Multiple EZH2 inhibitors, including tazemetostat (EPZ-6438), GSK2816126,
and CPI-1205, are currently in phase I or phase II clinical trials for patients with
lymphoma, leukemia, metastatic castration-resistant prostate cancer, non-small
cell lung cancer, and other cancers. Importantly, tazemetostat is well tolerated
and showed antitumor activity in a phase I trial of B-cell non-Hodgkin lymphoma
and advanced solid tumors (116). Tazemetostat also showed promising
anticancer

effects

in

a

phase

I

study

of

INI1-negative

tumors

or

relapsed/refractory synovial sarcoma. However, none of the EZH2 inhibitors has

79

been tested for breast cancer, in which the EZH2 protein level is known to be
highly elevated. It should be noted that in our study, we found that TNBC cells
are resistant to enzymatic inhibition of EZH2 by GSK126 but sensitive to EZH2
depletion (Figure 2), suggesting that the tumor-promoting function of EZH2 in
TNBC depends largely on its non-catalytic activity. Thus, it is important to inhibit
both catalytic and non-catalytic activity of EZH2 instead of only its enzymatic
activity to inhibit EZH2-dependent tumors, such as TNBC. Inhibiting the protein
level should be an effective way to simultaneously suppress EZH2’s catalytic and
non-catalytic activity.
Several ubiquitin ligases, such as β-TrCP and SMURF2, promote EZH2
degradation via the ubiquitin-proteasome pathway (62, 117, 118). Destabilization
of EZH2 by targeting its deubiquitinase may offer an alternative therapeutic
approach for treating EZH2-overexpressing tumors such as TNBC. In our study,
by screening a human deubiquitinase ORF library, we identified the OUT family
member, ZRANB1, as the first EZH2 deubiquitinase that regulates the
polyubiquitination and protein stability of EZH2 (Figure 19). Depletion of
ZRANB1 generally resulted in the destabilization of EZH2 and inhibition of cell
proliferation in TNBC cells. Importantly, systemic delivery of DOPC-encapsulated
ZRANB1 siRNA had marked antitumor and antimetastatic effects in xenograft
mouse models of TNBC. It should be noted that ZRANB1 protein levels
correlated significantly with EZH2 protein levels (R2 = 0.49) and poor survival
(HR = 2.6) in patients with breast cancer (with all breast cancer subtypes).
Considering that only ~20% of breast cancer is TNBC, this suggests that
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ZRANB1 may also regulate EZH2 and promote proliferation in non-TNBC breast
cancer cells. However, the regulation of EZH2 by ZRANB1 in non-TNBC needs
further investigation. Moreover, TCGA data analysis revealed that ZRANB1 gene
amplification was found in a subset of cases in breast cancer and ovarian cancer.
Collectively, ZRANB1 is a novel therapeutic target in breast cancer, especially in
TNBC.
Ablation of ZRANB1 is compatible with the viability of normal tissues, since
Zranb1-null mice were viable and did not exhibit phenotypic differences
compared with wild-type mice under normal physiological conditions, although
they

were

resistant

to

the

induction

of

experimental

autoimmune

encephalomyelitis (61). Similarly, our data revealed that ZRNAB1 siRNA
treatment was not detrimental to normal human and mouse cells and was not
toxic to mice (Figure 17). Notably, ZRANB1 protein is abundantly expressed in
TNBC cell lines, which are responsive to ZRANB1 siRNA or inhibitor, but is
undetectable in normal human mammary epithelial cell lines, which are resistant
to knockdown or chemical inhibition of ZRANB1. This suggests that contrary to
normal cells that are not dependent on ZRANB1, TNBC cells are functionally
dependent on ZRANB1 and sensitive to ZRANB1 depletion, indicating ZRANB1
as a promising anticancer target in TNBC.
In the current study, a small-molecule ZRANB1 inhibitor NSC112200
destabilized EZH2 through ubiquitination and the proteasome and inhibited cell
viability through, at least in part, ZRANB1. In contrast, it had no effect on EZH2
protein level and little effect on viability in normal mammary epithelial cells with
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no detectable ZRANB1 expression. It should be noted that NSC112200 is not
water soluble (dissolved in DMSO or corn oil), and that it inhibits ZRANB1’s DUB
activity, destabilizes EZH2, and kills TNBC cells at µM but not nM concentrations.
Moreover, some of the NSC112200-treated C57BL/6 mice exhibited acute
responses (low body temperature; reduced activity) in preliminary animal testing
(data not shown), indicating some toxicity. Thus, NSC112200 can serve as a tool
compound but may not behave in a drug-like manner in vivo. Nevertheless, here
we provide a proof of principle that the EZH2 deubiquitinase identified in this
study is amenable to inhibition by small molecules. This represents a starting
point to target ZRANB1. Considering that NSC112200 was from in silico
screening, further development of a clinical ZRANB1 inhibitor may involve lead
compound identification via high-throughput chemical screening, and the use of
the structure-activity relationship (SAR) analysis to optimize the activity,
selectivity, pharmacokinetics, safety profile, and physical properties of lead
compounds, which will enable full evaluation in animal models.
The regulation of EZH2 by ZRANB1 raises the question of whether ZRANB1
regulates additional proteins. Our study found that overexpression of EZH2 can
only partially rescue ZRANB1 siRNA- or gRNA-mediated severe growth defects
(Figure 13), indicating that ZRANB1 may also regulate other cancer-related
proteins. Indeed, although poorly studied, ZRANB1 has been reported to have
positive effects on Wnt/ β-catenin-mediated gene transcription and promotes
cancer cell growth (56, 119). Additionally, ZRANB1 may deubiquitinate and
stabilize Jmjd2d and thereby regulate inflammatory T cell responses via
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regulating the expression of Il12 and Il23 (61). Whether ZRANB1 deubiquitinates
and stabilizes other substrates needs to be investigated in future studies.
However, our findings that EZH2 largely rescued ZRANB1 depletion-caused
growth defect (Figure 13) suggest EZH2 as a main substrate of ZRANB1.

Figure 19. Proposed model for regulation of EZH2 by ZRANB1.
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Chapter 4: USP37 Is a SNAI1 Deubiquitinase
4.1 Introduction
More than 90% of cancer-related deaths are associated with tumor
metastasis (120), a multistep process in which cancer cells in the
primary tumor invade extracellular matrix (ECM) and stromal cell layers,
intravasate into the circulating and lymphatic systems, extravasate
through distant capillaries, and invade and proliferate to form secondary
metastases at distant organs (121, 122). Epithelial-to-Mesenchymal
transition (EMT), an important process in development, fibrosis, and
tumor metastasis (123), is characterized by loss of cell adhesion, repression
of E-cadherin expression, acquisition of mesenchymal markers, and increased
cell motility and invasiveness (124). Researchers initially identified and
characterized EMT in developmental biology as a phenomenon observed in early
embryonic formation and differentiation (125, 126). During development, EMT
has a pivotal role in enabling embryonic cells to migrate and form various organs
(123). In human adult cells, EMT is usually silent. However, during chronic
inflammation, EMT can be reactivated and various mesenchymal cells will be
derived to resolve injury (123). Importantly, cancer cells that have undergone
EMT become migratory and invasive during metastasis, enabling them to invade
surrounding tissues and migrate to distant organs (127, 128).
SNAI1, a zinc finger transcription factor that binds to two E2 BOXES
proximal to the transcriptional start site of the CDH1 gene, is a key inducer of
EMT and directly inhibits the expression of E-cadherin protein (129, 130). As a
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convergence point in EMT induction (131), SNAI1 has been closely implicated in
numerous EMT-dependent or EMT-independent functions. SNAI1 is reported to
be

necessary

for

tumor

growth

and

lymph

node

metastasis

(132).

Mechanistically, a transgenic mouse mammary tumor model study showed that
Snail is involved in breast cancer recurrence via E-cadherin suppression and
EMT induction (133). In addition, SNAI1-induced EMT not only enhances the
migratory capability of cancer cells but also suppresses host immune
surveillance to promote melanoma metastasis (134). Furthermore, accumulating
evidence indicates that SNAI1 has more functions in cancer progression in
addition to repressing E-cadherin and inducing EMT. In cultured cells and
developing embryos, SNAI1 impairs cell cycle progression via suppressing cyclin
D2 transcription in a context-dependent manner and confers resistance to cell
death by activating survival factors such as triggering the Mek/Erk and PI3K/Akt
survival pathways (135). In basal-like breast cancer, SNAI1 interacts with the
H3K9 methyltransferase G9a and DNA methyltransferase Dnmt1 to silence
fructose-1,6-biphosphatase

(FBP1)

expression,

causing

glycolytic

reprogramming to increase glucose uptake and macromolecule biosynthesis, and
to maintain ATP production under hypoxic conditions (136). It should be noted
that SNAI1 protein correlates positively with higher tumor grade, greater tumor
metastasis, and poor prognosis (129, 137, 138). Considering the important roles
of SNAI1 in cancer, a better understanding of SNAI1 regulation will provide
important information on preventing cancer progression and metastasis.
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SNAI1 gene expression is tightly regulated at the transcriptional level by
numerous signaling pathways, such as transforming growth factor β (TGFβ),
epidermal growth factor (EGF) and the Notch pathways (128). In addition, SNAI1
activity is regulated by its subcellular localization, which is governed by at least
two kinases GSK3β and PAK1, and by the zinc-finger transporter LIV1 (131).
Importantly, SNAI1 protein can be degraded through the ubiquitin-proteasome
pathway. SNAI1 is a labile protein with a short half-life that is actively degraded
through the ubiquitin-proteasome degradation pathway. Various E3 ligases such
as β-TrCP, Fbxl14, SCF-FBXO11, and FBW7 have been reported to be involved
in SNAI1 ubiquitination and degradation (139-142). However, DUBs that stabilize
SNAI1 and promote metastasis have not been as well studied. DUB3, a cytokineinducible DUB, is reported to promote breast cancer invasion and metastasis by
stabilizing SNAI1 protein (143, 144). In esophageal squamous cell carcinoma,
PSMD14 and OTUB1 prevented SNAI1 from degradation and promoted
metastasis (145, 146). In our study, we identified USP37 as another SNAI1 DUB,
which directly deubiquitinates SNAI1 and promotes cancer cell migration through
stabilizing SNAI1 protein.
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4.2 Results
4.2.1 USP37 regulates SNAI1 protein levels
To identify SNAI1 DUBs, we first screened for SNAI1-interacting DUBs
using a panel of 68 human SFB-tagged DUBs (103, 147). We transiently cotransfected each SFB-tagged DUB with MYC-tagged SNAI1 into HEK293T cells,
pulled down the DUBs with S-protein beads, and detected the physical
association of SNAI1 with 23 DUBs (Figure 20A). Because nearly one-third of
the 68 DUBs interacted with SNAI1 in the pulldown assay, we performed a
secondary screening to determine which DUBs affect SNAI1 protein levels. We
transfected the 23 SFB-DUBs individually into HEK293T cells and found that only
USP29, USP36, and USP37 markedly increased SNAI1 protein levels (Figures
20B and 20C). Importantly, the interaction between these three DUBs and SNAI1
was confirmed via pulldown of SFB-DUBs (Figure 20D). Reciprocally, each of
these three SFB-tagged DUBs could be pulled down by MYC-SNAI1, but not by
MYC-GFP (Figure 20E).
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Figure 20. USP29, USP36, and USP37 interact with SNAI1 and elevate
SNAI1 protein levels.
(A) 23 of 68 DUBs physically associated with SNAI1. Each SFB-tagged DUB was
co-transfected with MYC-SNAI1 into HEK293T cells, followed by pulldown with
S-protein beads and immunoblotting with antibodies against FLAG and MYC. (B)
Each SFB-tagged DUB was transfected into HEK293T cells, followed by
immunoblotting with antibodies against SNAI1, FLAG, and β-actin. (C)
Quantification of SNAI1 protein levels (normalized to β-actin) in (B). (D)
HEK293T cells were co-transfected with SFB-tagged DUBs and MYC-SNAI1,
followed by pulldown with S-protein beads and immunoblotting with antibodies
against FLAG and MYC. (E) HEK293T cells were co-transfected with SFBtagged DUBs and MYC-SNAI1 or MYC-GFP, followed by immunoprecipitation
with anti-MYC beads and immunoblotting with antibodies against FLAG and
MYC.
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To determine whether USP29, USP36, and USP37 promote SNAI1
deubiquitination, we co-transfected each of the DUBs with MYC-SNAI1 and HAubiquitin into HEK293T cells and treated the cells with MG132 to inhibit
proteasome degradation. USP44 was used as a negative control. USP29,
USP36, and USP37, but not USP44, reduced the polyubiquitination of SNAI1
(Figure 21A). To determine which of the three DUBs stabilizes the SNAI1
protein, we transiently transfected HEK293T cells with pBabe-SNAI1, MYC-GFP,
and SFB-tagged GFP or DUBs, treated the cells with 100 µg ml-1 CHX, and
determined pBabe-SNAI1 levels at different time points. Although all three DUBs
increased the steady-state level of SNAI1 protein, only USP29 and USP37
increased the half-life of ectopically expressed SNAI1 protein (Figures 21B and
21C).
Furthermore, bacterial purified His-SNAI1 protein could bind to mammalian
purified SFB-USP37, but not to SFB-GFP or SFB-USP29, under cell-free
conditions (Figure 21D), suggesting that USP37 may directly regulate SNAI1.
Collectively, these findings suggest that USP37 is a direct positive regulator of
SNAI1 protein.
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Figure 21. USP37 is a direct positive regulator of SNAI1 protein.
(A) HEK293T cells were co-transfected with HA-Ub, MYC-SNAI1, and SFBtagged DUBs, followed by immunoprecipitation with anti-MYC beads and
immunoblotting with antibodies against HA, MYC, FLAG and Hsp90. Cells were
treated

with

10

µM

MG132

for

6

hours

before

collection.

Before

immunoprecipitation, lysates were heated at 95°C for 5 minutes in the presence
of 1% SDS (for denaturing), followed by 10-fold dilution with lysis buffer and
sonication. (B) HEK293T cells were co-transfected with pBabe-SNAI1, MYCGFP, and SFB-tagged GFP or DUBs, treated with 100 µg ml-1 cycloheximide
(CHX), harvested at different time points, and then immunoblotted with
antibodies against SNAI1, MYC and FLAG. MYC-GFP serves as the control for
transfection. LE: long exposure; SE: short exposure. (C) Quantification of SNAI1
protein levels (normalized to MYC-GFP) in (B). (D) Left panel: SFB-GFP, SFBUSP29, and SFB-USP37 were purified from HEK293T cells transfected with
SFB-tagged GFP or DUBs, via pull-down with strepividin beads and followed by
elution with biotin. Purified SFB-GFP, SFB-USP29, or SFB-USP37 was
incubated with purified His-SNAI1, followed by pulldown with S-protein beads
and immunoblotting with antibodies against SNAI1 and FLAG. Right panel:
Purified proteins were analyzed by SDS-PAGE and Coomassie blue staining. (B)
was performed by Dr. Jongchan Kim.

92

4.2.2 USP37 stabilizes SNAI1 protein through deubiquitination
To further investigate the effect of USP37 on SNAI1, we co-expressed
SFB-USP37 with MYC-SNAI1 in HEK293T cells and treated the cells with or
without MG132 for 6 hours. Expression of wild-type (WT) USP37 markedly
increased SNAI1 protein levels, similar to the effect caused by MG132 treatment
(Figure 22A). However, the catalytically inactive mutant USP37C350S showed no
effect on SNAI1 protein levels (Figure 22A), suggesting that the enzymatic
activity of USP37 is required for elevating SNAI1 protein levels. To determine
whether USP37 stabilizes SNAI1 protein, we transfected HEK293T cells with
MYC-SNAI1 and USP37 or USP37C350S, treated the cells with 100 µg ml-1 CHX,
and determined MYC-SNAI1 levels at different time points. In HEK293T cells,
overexpression of WT USP37, but not USP37C350S, increased the half-life of
ectopically expressed MYC-SNAI1 protein (Figures 22B and 22C). Conversely,
knockdown of USP37 in HEK293T cells markedly shortened the half-life of
ectopically expressed MYC-SNAI1 protein (Figures 22D and 22E).
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Figure 22. USP37 stabilizes SNAI1 protein.
(A) HEK293T cells were transfected with SFB-GFP, SFB-USP37, or SFBUSP37C350S, treated with 10 µM MG132 for 6 hours, harvested and
immunoblotted with antibodies again SNAI1, FLAG, and β-actin. (B) HEK293T
cells were co-transfected with SFB-GFP, SFB-USP37, or SFB-USP37C350S and
V5-GFP, treated with 100 µg ml-1 cycloheximide (CHX), harvested at different
time points, and then immunoblotted with antibodies against MYC, V5, and
FLAG. V5-GFP served as the control for transfection. (C) Quantification of SNAI1
protein levels (normalized to V5-GFP) in (B). (D) HEK293T cells were cotransfected with MYC-SNAI1, V5-GFP, and USP37 siRNA #3 or scramble siRNA,
treated with 100 µg ml-1 CHX, harvested at different time points, and then
immunoblotted with antibodies against MYC, V5, β-actin, and FLAG. V5-GFP
served as the control for transfection. (E) Quantification of SNAI1 protein levels
(normalized to V5-GFP) in (D).
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We

reasoned

that

USP37

stabilizes

SNAI1

through

deubiquitination. First, we transiently transfected HEK293T cells with
HA-ubiquitin, MYC-SNAI1 and SFB-tagged USP37 or USP37C350S, and
then treated the cells with 10 µM MG132 for 6 hours. MYC-SNAI1 was
immunoprecipitated by anti-MYC beads, and its polyubiquitination was detected
by antibody against HA. As expected, overexpression of WT USP37, but not
USP37C350S, substantially reduced SNAI1 polyubiquitination (Figure 23A). To
further determine whether USP37 directly deubiquitinates SNAI1, we incubated
purified USP37 or USP37C350S and ubiquitinated SNAI1 purified from HEK293T
cells in a cell-free system. WT USP37 purified from HEK293T cells, but not
USP37C350S, markedly decreased SNAI1 polyubiquitination in vitro (Figure 23B),
indicating that USP37 can directly deubiquitinate SNAI1. Previous studies have
reported seven types of polyubiquitin chains (3). To determine which types of
polyubiquitination of SNAI1 can be removed by USP37, we performed a
deubiquitination assay using all seven lysine-specific mutants of ubiquitin (e.g.,
the K27 mutant contains only a single lysine, K27, with all other six lysine
mutated to arginine). In HEK293T cells, both K27- and K48-linked, but not other
lysine-linked, polyubiquitination of SNAI1 were reduced by the overexpression of
USP37 (Figure 23C). Furthermore, under denaturing conditions, USP37, but not
USP37C350S, strongly deubiquitinated K27- and K48-linked polyubiquitination of
SNAI1 (Figures 23D and 23E). Taken together, USP37 stabilizes SNAI1 protein
through deubiquitinating K27- and K48-linked polyubiquitination.
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Figure 23. USP37 stabilizes SNAI1 protein through deubiquitination.
(A) HEK293T cells were co-transfected with MYC-SNAI1, HA-ubiquitin (Ub), and
USP37 or SFB-USP37C350S, followed by immunoprecipitation with anti-MYC
beads and immunoblotting with antibodies against HA, FLAG and MYC. (B) SFBGFP, SFB-USP37, and SFB-USP37C350S were purified from HEK293T cells
transfected with SFB-tagged GFP or DUBs. Ubiquitinated MYC-SNAI1 was
purified with anti-MYC beads from HEK293T cells co-transfected with MYCSNAI1 and HA-Ub, and was incubated with puried SFB-tagged GFP or DUBs.
After the in vitro deubiquitination, bound proteins were eluted and immunoblotted
with antibodies against HA and MYC. Purified proteins were analyzed by SDSPAGE and Coomassie blue staining. (C) HEK293T cells were co-transfected with
MYC-SNAI1, SFB-GFP or SFB-USP37 and different mutants of HA-Ub, followed
by immunoprecipitation with anti-MYC beads and immunoblotting with antibodies
against HA, FLAG and MYC. (D) HEK293T cells were co-transfected with MYCSNAI1, SFB-USP37 or SFB-USP37C350S, and K27-linked HA-Ub, followed by
immunoprecipitation with anti-MYC beads and immunoblotting with antibodies
against HA, FLAG and MYC. (E) HEK293T cells were co-transfected with MYCSNAI1, SFB-USP37 or SFB-USP37C350S, and K48-linked HA-Ub, followed by
immunoprecipitation with anti-MYC beads and immunoblotting with antibodies
against HA, FLAG and MYC. Before immunoprecipitation, lysates were heated at
95°C for 5 minutes in the presence of 1% SDS (for denaturing), followed by 10fold dilution with lysis buffer and sonication in (A), (D), and (E).
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4.2.3 USP37 regulates SNAI1 protein levels and promotes cancer cell
migration
To further determine whether USP37 regulates endogenous SNAI1 protein,
we individually transfected three independent USP37 siRNAs (#1, #2, and #3) or
the scramble siRNA into HEK293T cells and found that all three USP37 siRNAs
reduced

endogenous

SNAI1

protein

levels

(Figure

24A).

Conversely,

overexpression of WT USP37 increased endogenous SNAI1 protein levels,
whereas the catalytically inactive mutant USP37C350S did not (Figure 24B).
Although USP37 consistently stabilized SNAI1 in HEK293T cells, the regulation
of SNAI1 by USP37 in cancer cells is unknown. Therefore, we transfected two
independent USP37 siRNAs (#2 and #3) into SUM159 cells, which have high
levels of endogenous SNAI1. Importantly, both siRNAs drastically reduced
SNAI1 protein levels (Figure 24C). In contrast, overexpression of WT USP37,
but not USP37C350S, increased endogenous SNAI1 protein level (Figure 24D),
suggesting that the catalytic function of USP37 is needed to stabilize SNAI1
protein. Similarly, in HCT116 cells, siRNA-mediated knockdown of USP37 led to
SNAI1 downregulation (Figure 24E) and overexpression of WT USP37, but not
USP37C350S, significantly elevated endogenous SNAI1 protein levels (Figure
24F).
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Figure 24. USP37 regulates SNAI1 protein levels.
(A) Immunoblotting with antibodies against USP37, SNAI1, and β-actin in
HEK293T cells transfected with USP37 siRNA or a scramble control (NC). (B)
Immunoblotting with antibodies against FLAG, SNAI1, and β-actin in HEK293T
cells transfected with SFB-GFP, SFB-USP37, or SFB-USP37C350S. (C)
Immunoblotting with antibodies against USP37, SNAI1, and β-actin in SUM159
cells transfected with USP37 siRNA or a scramble control (NC). (D)
Immunoblotting with antibodies against FLAG, SNAI1, and β-actin in SUM159
cells transfected with SFB-GFP, SFB-USP37, or SFB-USP37C350S. (E)
Immunoblotting with antibodies against USP37, SNAI1 and β-actin in HCT116
cells transfected with USP37 siRNA or a scramble control (NC). (F)
Immunoblotting with antibodies against FLAG, SNAI1, and β-actin in HCT116
cells transfected with SFB-GFP, SFB-USP37, or SFB-USP37C350S.
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SNAI1-induced

EMT

has

been

reported

to

promote

cancer

metastasis (134). To determine the biological function of USP37 in
cancer cells, we transiently transfected WT USP37 or USP37C350S into
SUM159 cells (Figure 24C) and performed Transwell migration assay.
WT USP37, but not USP37C350S, markedly increased cell migration
(Figure 25A). A similar effect was observed in HCT116 cells (Figures
24E and 25B). Conversely, we generated HCT116 cells stably silencing
USP37 expression using USP37 shRNAs and found that knockdown of
USP37 expression downregulated SNAI1 protein levels (Figure 25C). As
expected, shRNA-mediated knockdown of USP37 in HCT116 cells led to
a prominent decrease in cell migration (Figure 25D). Notably, silencing
USP37 expression did not significantly affect cell proliferation (Figure
25E).
We then asked whether SNAI1 is a functional effector of USP37.
We transiently transfected MYC-GFP or MYC-SNAI1 into HCT116 cells
transduced with USP37 shRNA or the control shRNA and then performed
Transwell migration assay. Ectopic expression of SNAI1 in USP37knockdown

HCT116

cells

largely

rescued

USP37

shRNA-induced

inhibition of cell migration (Figures 26A and 26B). Taken together, these
findings indicate that USP37 promotes cancer cell migration and that its
function is mediated, at least in part, by its substrate SNAI1.
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Figure 25. USP37 promotes cancer cell migration.
(A and B) Transwell migration assay of SUM159 (A) or HCT116 cells (B)
transfected with SFB-GFP, SFB-USP37, or SFB-USP37C350S. (C) Immunoblotting
of USP37, SNAI1, and β-actin in HCT116 cells transduced with scramble (NC) or
USP37 shRNA. (D) Transwell migration assay of HCT116 cells transduced with
scramble or USP37 shRNA. (E) Growth curves of HCT116 cells transduced with
scramble or USP37 shRNA. n = 3 biological replicates. Error bars in (A), (B), (D),
and (E) are s.e.m. P values were calculated from a two-tailed t-test.
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Figure 26. USP37 promotes cancer cell migration through SNAI1.
(A) Immunoblotting of USP37, SNAI1, and β-actin in HCT116 cells transduced
with USP37 shRNA or a scramble control with or without MYC-SNAI1
overexpression. (B) Transwell migration assay of HCT116 cells transduced with
USP37 shRNA or a scramble control with/without MYC-SNAI1 overexpression.
Error bars are s.e.m. P values were calculated from a two-tailed t-test.
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4.3 Discussion
Tumor metastasis is the primary cause of cancer-related mortality.
Although several studies suggest that EMT might be dispensable for
metastasis in pancreatic cancer, ovarian cancer, and lung cancer (148150), most findings indicate that EMT has an important role in inducing
metastasis, involving multiple transcriptional factors such as SNAI1,
Twist, and Zeb1 (129, 151, 152). SNAI1 is a key inducer of EMT and
directly inhibits the expression of the E-cadherin protein (129). SNAI1
protein is usually silenced in adult cells but is re-expressed during
certain processes such as wound healing and inflammation (153). In
metastatic cancer, SNAI1 functions to regulate cancer recurrence, tumor
metastasis, immune evasion, cancer progression, cell cycle progression,
cell death, and cancer metabolism (134-137). Notably, SNAI1 protein levels
are positively correlated with higher tumor grade, tumor metastasis and poor
prognosis (129, 137, 138). However, because SNAI1 is a transcription factor
localized predominantly in the nucleus, it is difficult to directly target SNAI1 by
small-molecule inhibitors. To date, only a few chemical inhibitors have been
reported to target SNAI1, including Co(III)-EBox, which inhibits the SNAI1/Ecadherin interaction (154). Considering the important roles of SNAI1 in cancer,
identifying targets upstream of SNAI1 that are amenable to drug-based
intervention could be a promising strategy to prevent cancer metastasis.
SNAI1 is a short-lived protein and its protein level is tightly
controlled by the ubiquitin-proteasome system-mediated degradation.
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Various E3 ligases such as β-TrCP, Fbxl14, SCF-FBXO11, and FBW7
have been implicated in SNAI1 ubiquitination and degradation (139-142).
Deubiquitinating enzymes could reverse SNAI1 polyubiquitination and
stabilize SNAI1 protein. DUB3, PSMD14, and OTUB1 were recently
reported to deubiquitinate SNAI1 and promote tumor metastasis in breast
cancer or esophageal squamous cell carcinoma (143-146). DUB3 did not
stand out as a SNAI1-interacting DUB in our initial screening, indicating
that the interaction between DUB3 and SNAI1 may not be strong enough
in HEK293T cells and that screening methods other than our interaction
screen may identify additional weak-interacting SNAI1 DUBs. Notably, we
previously used the same approach to successfully identify the DUBs for PTEN,
EZH2, YAP, and β-catenin (13, 57, 103, 155), suggesting that our screening
system is unbiased and valuable. In our screen, we found that OTUB1 interacted
with SNAI1 (Figure 20A); however, OTUB1 did not increase SNAI1 protein levels
as much as USP29, USP36, or USP37 did (Figure 20B), indicating that OTUB1
may not play a major role in stabilizing SNAI1 protein in our system.
Here we proposed USP37 as a SNAI1 deubiquitinase that promotes
cancer cell migration. Notably, USP37 is highly expressed in breast
cancer and its expression positively correlates with mortality rates (156).
Qin et al. reported that USP37 could interact with and stabilize Gli-1 (a
Hedgehog [Hh] pathway component) and regulate the stemness, cell invasion,
and EMT via the Hh pathway (156). Other proteins have also been reported as
USP37 substrates. For example, USP37 regulates the stability of oncogenic
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proteins 14-3-3γ (157), PLZF/RARA (158), and c-Myc (159). USP37 also plays
an important role in regulating DNA replication via deubiquitinating Cdt1 (160).
Considering its critical role in several cancer types, USP37 is emerging as a
promising therapeutic target (156, 159).
In our study, we report USP37 as another SNAI1 DUB that functions to
deubiquitinate and stabilize SNAI1. We showed that (1) USP37 directly interacts
with and deubiquitinates SNAI1; (2) USP37 stabilizes SNAI1 protein and
promotes cancer cell migration; and (3) USP37 induces cell migration through
SNAI1, at least partially. These results suggest USP37 as a novel antimetastatic
target in cancer therapy.
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Chapter 5: Future Directions
5.1 The EZH2 deubiquitinase ZRANB1 as a therapeutic target in
breast cancer
Although previous studies attributed the cancer-promoting function of EZH2
to its enzymatic function of methylating histone H3 and repressing PRC2 target
genes (114), accumulating evidence has demonstrated that the non-catalytic
activity of EZH2 contributes substantially to tumor formation and progression (97,
98, 100, 101). Indeed, many cancers do not respond to EZH2 enzymatic
inhibitors. In Chapter 3, we identified ZRANB1 as the deubiquitinase of EZH2
and a potential therapeutic target in TNBC. ZRANB1 binds, deubiquitinates, and
stabilizes EZH2. Depletion of ZRANB1 generally resulted in downregulation of
EZH2 protein and inhibition of cell proliferation in TNBC cells. Overexpressing
EZH2 in TNBC cells markedly rescued ZRNAB1 siRNA-induced severe growth
defects, suggesting that ZRANB1 promotes TNBC cell proliferation via EZH2. In
future studies, it will be interesting and necessary to determine whether ZRANB1
promotes tumor growth and metastasis through EZH2 in vivo using TNBC mouse
models.
Importantly, overexpressing the catalytically inactive mutant of EZH2 in
TNBC cells largely rescued ZRNAB1 siRNA-induced severe growth defect,
suggesting that the non-catalytic function of EZH2 plays an important role in
TNBC.

For

example,

EZH2

may

catalytic-independently

activate

gene

transcription via physical interaction with ER and β-catenin in breast cancer
(100). Moreover, EZH2 has been reported to regulate NF-κB gene expression
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under context-specific conditions in breast cancer. Specifically, in ER-negative
basal-like

breast

cancer,

EZH2

enzymatic-independently

interacts

with

RelA/RelB and therefore promotes the expression of NF-κB target genes (101).
However, whether EZH2 promotes TNBC tumor growth and metastasis through
other non-enzymatic functions needs to be further investigated.
In Chapter 3, we found that ZRANB1 protein levels correlated significantly
with EZH2 protein levels (R2 = 0.49) and poor survival (HR = 2.6) in patients with
breast cancer (including both TNBC and non-TNBC). Considering that only ~20%
of breast cancer is TNBC, ZRANB1 may also regulate EZH2 and promote
proliferation in non-TNBC cells, which warrants further investigation. Indeed, in
our preliminary findings, the non-TNBC breast cancer cell lines SKBR3 (ER−
HER2+) and MCF7 (ER+ HER2−) showed EZH2 downregulation and severe
growth inhibition upon ZRANB1 depletion (Figure 27). However, non-TNBC
breast cancer cell lines T47D (ER+ HER2−) and ZR75-1 (ER+ HER2+) showed
different responses: knockdown of ZRANB1 did not significantly affect the
proliferation of T47D and ZR75-1 cells, even though EZH2 was downregulated in
both cell lines (Figure 27). The inconsistent responses of non-TNBC cells
towards ZRANB1 depletion are particularly interesting. Importantly, in all
examined human breast cancer cells (both TNBC and non-TNBC), ZRANB1
depletion significantly downregulated EZH2 protein, suggesting that ZRANB1 is a
general regulator of EZH2 in breast cancer cells. However, unlike TNBC cell lines
that consistently showed severe growth defects upon ZRANB1 knockdown, nonTNBC cell lines (ER+ or HER2+) responded variously (responsive or insensitive)
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to ZRANB1 depletion, indicating that ZRANB1 may have greater functional
importance and better therapeutic potential in TNBC than in non-TNBC. This may
reflect that some of the non-TNBC breast cancer cells are not dependent on
ZRANB1 and EZH2 for their proliferation. However, identifying subtypes of nonTNBC that do not depend on the function of ZRANB1 and EZH2 needs further
exploration.
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Figure 27. Effects of ZRANB1 knockdown on non-TNBC breast cancer cell
lines.
(A) qPCR of ZRANB1 in four non-TNBC (ER+ or HER2+) breast cancer cell lines
transfected with ZRANB1 siRNA or a scramble control. n = 3 biological
replicates. (B) Immunoblotting of EZH2 and β-actin in four non-TNBC (ER+ or
HER2+) breast cancer cell lines transfected with ZRANB1 siRNA or a scramble
control. (C) Growth curves of four non-TNBC (ER+ or HER2+) breast cancer cell
lines transfected with ZRANB1 siRNA or a scramble control. Cells were seeded
in 6-well plates. n = 3 biological replicates. Error bars in (A) and (C) are s.e.m. P
values were calculated from a two-tailed t-test.
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5.2 The SNAI1 deubiquitinase USP37 as an antimetastatic target
USP37 has been reported to stabilize several oncoproteins such as
the Hedgehog (Hh) pathway component Gli-1 (156), 14-3-3γ (157),
PLZF/RARA (158), and c-Myc (159). Considering its critical role in
multiple cancer types, USP37 is emerging as a promising therapeutic
target (156, 159). In our study, we identified another mechanism by
which

USP37

promotes

metastasis

—

via

stabilizing

SNAI1.

Overexpression of USP37, but not its catalytically inactive mutant
C350S, significantly stabilized SNAI1 protein through deubiquitination
and increased cell migration, whereas knockdown of USP37 markedly
inhibited cell migration (Figure 25). However, more work is needed to
reveal the mechanisms underlying USP37-mediated SNAI1 stabilization
to promote migration and metastasis. For example, it would be
interesting to determine the domains of SNAI1 and USP37 responsible
for their interaction. In addition, to confirm that USP37 promotes tumor
metastasis through stabilizing SNAI1 protein in vivo using mouse models
is necessary not only to validate our findings in tumor cells but also to
provide evidence that USP37 is a promising antimetastatic target.
Post-translational modifications of substrate proteins, such as
phosphorylation or hydroxylation, have been reported to regulate protein
ubiquitination

and

degradation.

Indeed,

the

E3

ligase

β-TrCP1

polyubiquitinates SNAI1 in a GSK-3β phosphorylation-dependent manner
(141). PDK1-mediated phosphorylation of SNAI1 induces the degradation
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of SNAI1 protein by FBXO11 (139). Importantly, additional sites of SNAI1
have been reported to be phosphorylated by other kinases, such as p21activated

kinase

(Pak1)

and

ATM

(161,

162).

Whether

the

phosphorylation of SNAI1 by specific kinases regulates its interaction
with USP37 remains unclear and is of particular interest for further
investigation.
Phosphorylation has been reported to positively or negatively
modulate the activity of DUBs (163). Indeed, cyclin-dependent kinase 2
(CDK2) has been reported to phosphorylate USP37 and enhance its
catalytic activity in a cell cycle-dependent manner (164). Considering
that USP37 has multiple predicted phosphorylation sites, whether
phosphorylation of USP37 at other sites stimulates its catalytic activity
would be valuable to know.
USP37 is highly expressed in breast cancer, and bioinformatics
analyses have correlated high USP37 levels with increased mortality
rates (156). Further investigation of whether high USP37 levels correlate with
high SNAI1 protein levels and poor outcomes using clinical breast/colon tumor
samples would be useful to determine whether USP37 is a clinically relevant
antimetastatic target. Additionally, whether the interaction of USP37 and SNAI1
is enhanced in tumors with higher grade would be interesting to examine.
Collectively, the success of this project would reveal details of the
mechanisms by which USP37 regulates SNAI1 protein and cell migration, and
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would provide evidence for targeting USP37 as a new and promising strategy for
antimetastatic therapy.

5.3 Deubiquitinases as potential therapeutic targets
In Chapter 3, we showed that the small-molecule ZRANB1 inhibitor
NSC112200 destabilized EZH2 through the ubiquitination-proteasome system
and strongly inhibited cell viability through, at least in part, ZRANB1. Notably, in
normal mammary epithelial cells with low levels of ZRANB1 protein, the inhibitor
had no effect on EZH2 protein level and little effect on cell viability. Unfortunately,
NSC112200 may not be useful as a drug because it functions at µM
concentrations in cells and caused acute responses (low body temperature;
reduced activity) in our preliminary animal testing. Nevertheless, in Chapter 3 we
provided a proof-of-principle that the EZH2 deubiquitinase ZRANB1 is amenable
to inhibition by small molecules, which warrants further investigation. For
example,

high-throughput

chemical

screening

and

the

structure-activity

relationship (SAR) analysis to optimize the compound activity, selectivity,
pharmacokinetics, safety profile, and physical properties may be performed in
future studies to identify a clinical ZRANB1 inhibitor. In addition, small molecules
that block the interaction of ZRANB1 and EZH2 may also be valuable and need
further exploration.
Because few chemicals can directly target SNAI1, more studies focused on
identifying molecules that target molecules upstream of SNAI1 to indirectly affect
SNAI1. In Chapter 4, we demonstrated that the SNAI1 deubiquitinase USP37
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might be a novel antimetastatic target. Although no USP37 inhibitor has been
reported, the role of USP37 in stabilizing oncogenic proteins like c-Myc (159),
14-3-3γ (157), or cyclin A (164) supports its being a putative therapeutic target
in cancer treatment. Screening for the chemicals that catalytically inhibit USP37
or block the interaction of USP37 and SNAI1 would be another promising
direction for future studies.
Most proteins can be degraded through the ubiquitin-proteasome system
and regulated by deubiquitinases. Inhibiting the upstream DUBs may be a better
strategy to target proteins with both catalytic-dependent and catalyticindependent functions or proteins that are difficult to directly inhibit by chemicals,
such as EZH2 and SNAI1 in our study. DUBs are involved in numerous signaling
pathways and regulate multiple processes such as the DNA damage response,
cell cycle control, and chromatin remodeling. Therefore, deregulation of DUBs
contributes significantly to tumor formation and progression. To date, inhibition of
DUBs has been a successful approach to tumor suppression (3). For example,
knockdown of USP36 reduced c-MYC and suppressed cell proliferation in lung
cancer (165). Depletion of USP15 downregulated MDM2 and attenuated tumor
growth (166). BAP1 knockdown decreased KLF5 protein and significantly
inhibited tumorigenicity and metastasis in breast cancer (167). These findings
suggest that DUBs would be attractive and promising therapeutic targets for
cancer treatment.
Although challenging, the development of small molecule inhibitors of DUBs
has shown some progress as well (168). On the one hand, DUB inhibitors
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themselves may be effective therapeutic strategies for cancer treatment. For
example, multiple DUB inhibitors as single agents have been reported to
significantly induce tumor cell apoptosis, such as cyclopentenone prostaglandins,
WP1130, VLX1570, and P5091 (50-54). NSC112200, characterized as a
ZRANB1 inhibitor, markedly induced severe cell death in TNBC cells (56, 57). On
the other hand, combination treatment of DUB-targeting agents with other drugs
may provide an alternative approach for cancer therapy. For example, pimozide
(an anti-psychotic drug) and GW7647 (a PPAR-α agonist), inhibitors of the
USP1/UAF1 deubiquitinase complex, were found to reverse the resistance of
non-small cell lung cancer cells to cisplatin (55). Moreover, concurrent inhibition
of DUBs and autophagy led to synergistic death of breast cancer cells (58).
Considering the optimized techniques to identify protein-based inhibitors and to
demystify protein structures, DUB inhibitors with improved efficacy, specificity,
and safety may emerge as new agents for cancer treatment in the near future.
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